How many companies are developing Pancreatic Ductal Adenocarcinoma (PDAC) treatments?

6 companies have active or registered Pancreatic Ductal Adenocarcinoma (PDAC) programs in TheraRadar's competitive landscape (83 classified trials). The most active are Astellas Pharma Global Development, Revolution Medicines, and Amplia Therapeutics Limited.

What mechanisms of action are being developed for Pancreatic Ductal Adenocarcinoma (PDAC)?

5 distinct mechanisms of action appear across the Pancreatic Ductal Adenocarcinoma (PDAC) pipeline, including Claudin 18.2, Pan-RAS / RAS(ON) multi, FAK, KRAS G12D, and VEGFR/Aurora B/CSF1R (multi-kinase).

What is the most crowded mechanism in Pancreatic Ductal Adenocarcinoma (PDAC)?

Claudin 18.2 is the most contested mechanism in Pancreatic Ductal Adenocarcinoma (PDAC), with 6 programs mapped to it.

Are there upcoming Pancreatic Ductal Adenocarcinoma (PDAC) clinical readouts or FDA decisions?

Near-term Pancreatic Ductal Adenocarcinoma (PDAC) catalysts include zolbetuximab (data readout, Aug '26); avutometinib (VS-6766) (data readout, Aug '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.

Where does TheraRadar's Pancreatic Ductal Adenocarcinoma (PDAC) landscape data come from?

Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.

Landscape / Oncology

Page updated Jul 4, 2026 · using data updated on Jun 28, 2026

Pancreatic Cancer Clinical Trial Landscape

Pancreatic cancer is a disease in which malignant cells form in the tissues of the pancreas, an organ located behind the stomach. While relatively rare, it is often diagnosed at later stages, making treatment challenging.

The clinical trial landscape for pancreatic cancer is active, with 1,527 trials registered since 2008, and 642 currently active (recruiting, enrolling, or active but not recruiting). Activity is heavily concentrated in early-phase trials, with 315 active Phase 1 trials out of 787 total, and 415 active Phase 2 trials out of 921 total.

Phase 3 trials account for 70 active trials out of 133 total, while Phase 4 trials are less common, with only 10 active trials out of 23 total. Revolution Medicines, Inc. leads industry sponsorship with 9 active trials, followed by AstraZeneca (7 active), Astellas Pharma Global Development, Inc. (6 active), Seagen, a wholly owned subsidiary of Pfizer (6 active), and Eli Lilly (4 active).

The high volume of Phase 1 and 2 trials suggests a strong focus on novel therapeutic approaches and early-stage drug development in this indication.

Trial activity

654 active / 1,562 total since 2008

Active by phase 73 Ph3 / 136 400 Ph2 / 908 170 Ph1 / 494 11 Ph4 / 24

Competitive Intelligence

This Pancreatic Cancer competitive landscape maps 6 companies against 5 mechanisms of action (MOA) across 8 active drug-development programs. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in Pancreatic Cancer, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

Beta 6 companies 5 mechanisms 8 programs mapped all shown mechanisms rule/db-classified ⏰ 2 due ≤6 mo click any cell → asset tearsheet

At a glance

Pancreatic Ductal Adenocarcinoma (PDAC) shows 8 programs across 6 companies and 5 mechanisms. The most contested mechanism is Claudin 18.2 (6 programs).

Key findings

55% of Claudin 18.2 programs (6 of 11) are combos with novel agents — class-extension work, not class-validation.
Top 3 mechanisms (Claudin 18.2, KRAS G12D, Chemo (Gem/nab-paclitaxel)) account for ~24% of programs — class concentration is low.
Astellas Pharma Global Development runs 5 programs — the deepest pipeline in this view.
Jiangsu Healthy Life Innovation Medical Technology has the highest composite score (100) — most-imminent / most-advanced asset weighted higher than program count.
15 hot readouts in next 6 months — most imminent: Can-Fite BioPharma (A3 ADENOSINE RECEPTOR).
18 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
48 single-program mechanisms in the long tail — 17 are Ph2+ first-in-class first-mover bets.
44 NME candidates in the long tail.
Most-novel-of-novel: Eleison Pharmaceuticals LLC. Alkylating agent (Ph3) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 2 due ≤6 mo

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet.

⏰ Due soon Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →

	Claudin 18.2	Pan-RAS / RAS(ON) multi	FAK	KRAS G12D	VEGFR/Aurora B/CSF1R (multi-kinas…
Astellas Pharma Global Develo…
Revolution Medicines
Amplia Therapeutics Limited
CARsgen
Chipscreen
Verastem

Phase 3 leaders · most advanced

recruiting Pfizer NCT06989437
active Arcus Biosciences, Inc. NCT06608927
recruiting Immuneering Corporation NCT07562152
recruiting GE Healthcare NCT07219238
recruiting NRG Oncology NCT06958328

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 2 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.

⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes

Single-program mechanisms (48) — one program each — earliest-stage, sorted by phase

Phase	Mechanism	Company	Modality	Readout	Trial
Ph3	Albumin-bound taxane ⚡ 🌱 ⚙️	CSPC ZhongQi Pharmaceutic…	IV	⏰ 2Q26	NCT06492941
Ph3	Alkylating agent ⚡ 🌱 🆕 ⚙️	Eleison Pharmaceuticals L…	IV	⏰ 2Q26	NCT01954992
Ph2+Ph3	c-MET ADC 🌱 🆕	AbbVie	IV	2Q31	NCT07490301
Ph3	FAP imaging 🌱 🆕	SOFIE	Radioligand	4Q27	NCT07217717
Ph2+Ph3	GDF-15 (cachexia) 🌱 🆕	Pfizer		1Q28	NCT06989437
Ph3	MEK / pan-RAF ⚡ 🌱 🆕	Immuneering Corporation		2Q28	NCT07562152
Ph2+Ph3	Multikinase (VEGFR/FGFR/CSF1R) ⚡ 🌱 🆕	Hutchmed	IV	2Q28	NCT06361888
Ph3	P-selectin inhibitor ⚡ 🌱 🆕 ⚙️	Quercis Pharma		4Q27	NCT06861088
Ph2+Ph3	TGF-β2 antisense 🌱 🆕	Oncotelic		⏰ 2Q26	NCT06079346
Ph3	Tissue factor ADC ⚡ 🌱 🆕	Lepu Biopharma		2Q27	NCT07138846
Ph2	A3 ADENOSINE RECEPTOR ⚡ 🌱 🆕	Can-Fite BioPharma		⏰ 3Q26	NCT06387342
Ph2	Botanical extract (BioLite) 🌱 🆕	Rgene Corporation	IV	2Q27	NCT03301805
Ph1+Ph2	CD40 agonist ⚡ 🌱 🆕	Alligator Bioscience AB		⏰ 2Q26	NCT04888312
Ph2	Corticosteroid 🌱	Corcept	IV	3Q27	NCT07259317
Ph2	CSF1R ⚡ 🌱 🆕	Abbisko		4Q25	NCT06111274
Ph2	CTLA-4 (Fc-enhanced) 🌱 🆕	Nelum	IV	1Q29	NCT07578337
Ph2	CXCL12 (anti-CXCL12 L-RNA aptamer) ⚡ 🌱 🆕	TME Pharma	IV	1Q28	NCT04901741
Ph2	EphA2 ADC ⚡ 🌱 🆕	BicycleTx Limited		1Q29	NCT07450859
Ph1+Ph2	FAK inhibitor 🌱 🆕	InxMed (Shanghai)	IV	4Q25	NCT05827796
Ph2	GMCI / gene therapy 🌱 🆕	Candel		4Q25	NCT02446093
Ph1+Ph2	HISTONE DEACETYLASE ⚡ 🌱 🆕	CG	Oral	⏰ 2Q26	NCT05249101
Ph2	IL-2 🌱 🆕	Salspera	IV	4Q30	NCT04589234
Ph2	IL-21 ⚡ 🌱 🆕	Hangzhou Converd		4Q28	NCT07006077
Ph2	KRAS 🌱 🆕	Verastem	IV	2Q27	NCT07644559
Ph2	KRAS G12C 🌱 🆕	Allist		⏰ 4Q26	NCT06008288
Ph2	KRAS G12D degrader 🌱 🆕 ⚙️	Ranok Therapeutics (Hangz…		⏰ 4Q26	NCT07303465
Ph2	mRNA neoantigen vaccine 🌱 🆕	Roche / Genentech	IM	1Q31	NCT05968326
Ph2	Nanofiber-based chemotherapy ⚡ 🌱 🆕 ⚙️	CEBIOTEX		3Q28	NCT06538857
Ph1+Ph2	PARP 🌱 🆕	Onconic	IV	2Q30	NCT05257993
Ph1+Ph2	PAUF mAb ⚡ 🌱 🆕	Prestige Biopharma Limited	IV	1Q26	NCT05141149
Ph2	PD-1 / VEGF bispecific 🌱 🆕	Akeso		3Q27	NCT07114315
Ph1+Ph2	PD-L1 (avelumab) 🌱	Vaccinex	IV	4Q28	NCT05102721
Ph2	PD-L1 / VEGF-A bispecific antibody 🌱 🆕	BioNTech	IV	4Q27	NCT07255404
Ph2	PD-L1 ADC 🌱 🆕	Shanghai Henlius		1Q28	NCT07301229
Ph1+Ph2	Radioprotectant ⚡ 🌱 🆕 ⚙️	Xerient Pharma		3Q29	NCT07157033
Ph1+Ph2	RAGE ⚡ 🌱 🆕	Cantex		1Q25	NCT05766748
Ph1	Anti-CD73 (ONO-7913) 🌱 🆕	Ono	IV	⏰ 4Q26	NCT06532344
Ph1	Autologous DC therapy ⚡ 🌱 🆕 ⚙️	Diakonos Oncology Corpora…		⏰ 2Q26	NCT04157127
Ph1	B7-H6 bispecific 🌱 🆕	Boehringer Ingelheim		⏰ 4Q26	NCT06882746
Ph1	FAP radioligand ⚡ 🌱 🆕 ⚙️	Chengdu New Radiomedicine…		4Q27	NCT06278454
Ph1	IL-15 superagonist 🌱 🆕	ImmunityBio	IV	2Q27	NCT07488884
Ph1	Integrin αvβ3 🌱	ProDa	IV	2Q27	NCT06182072
Ph1	Local paclitaxel device ⚡ 🌱 🆕	PanTher		⏰ 3Q26	NCT06673017
Ph1	Multi-antigen T-cell ⚡ 🌱 🆕	Marker		3Q28	NCT06549751
Ph1	MYC ⚡ 🌱 🆕	Peptomyc S.L.	IV	⏰ 2Q26	NCT06059001
Ph1	Oncolytic virus 🌱 🆕 ⚙️	Boehringer Ingelheim		1Q27	NCT05846516
Ph1	PD-1 (nivolumab) 🌱 🆕	Ono	IV	3Q27	NCT06532331
Ph1	TLR9 agonist ⚡ 🌱 🆕 ⚙️	TriSalus Life Sciences		3Q27	NCT05607953

Emerging & small-cap sponsors (19) — few programs here — partnering / M&A radar

Phase	Mechanism	Company	Modality	Readout	Trial
Ph1	MTAP / PRMT5	Amgen	IV	⏰ 4Q26	NCT06360354
Ph3	Chemo (FOLFIRINOX/FOLFOX/FOLFIRI) ⚡	Angiodynamics	IV	2Q25	NCT03899636
Ph1+Ph2	Claudin 18.2	Anova Innovation Limited	IV	3Q27	NCT07444541
Ph2	🇨🇳 VEGFR	Chia Tai Tianqing Pharmac…	Oral	⏰ 4Q26	NCT06767813
Ph1	Claudin 18.2	Dong-A ST		1Q28	NCT07481357
Ph2	Chemo (FOLFIRINOX/FOLFOX/FOLFIRI) ⚡	EXACT Therapeutics AS	IV	⏰ 4Q26	NCT06850623
Ph3	🇨🇳 Claudin 18.2	FutureGen Biopharmaceutic…	IV	2Q30	NCT07383922
Ph3	🇨🇳 KRAS G12D	Genfleet Therapeutics (Sh…		2Q27	NCT07262567
Ph3	KRAS G12D	Incyte Corporation		3Q28	NCT07522073
Ph3	🇨🇳 Claudin 18.2	Innovent Biologics (Suzho…		2Q27	NCT07066098
Ph1+Ph2	Chemo (Gem/nab-paclitaxel)	Jacobio	Oral	4Q29	NCT07640295
Ph3	🇨🇳 Chemo (Gem/nab-paclitaxel)	Jiangsu Healthy Life Inno…	IV	⏰ 4Q26	NCT05653453
Ph3	🇨🇳 KRAS G12D	Jiangsu HengRui Medicine		2Q29	NCT07232875
Ph1	Claudin 18.2	Legend		4Q27	NCT05539430
Ph2	Chemo (FOLFIRINOX/FOLFOX/FOLFIRI) ⚡	OncoSil Medical Limited	IV	1Q26	NCT05466799
Ph3	🇨🇳 VEGFR	Shanghai Chia Tai Tianqin…	IV	2Q28	NCT07165951
Ph3	🇨🇳 Chemo (Gem/nab-paclitaxel)	Shanghai Yizhong	IV	3Q27	NCT06752811
Ph2	Chemo (Gem/nab-paclitaxel)	SynerGene	IV	⏰ 4Q26	NCT02340117
Ph1+Ph2	MTAP / PRMT5	Tango	IV	2Q27	NCT06922591

Unclassified programs (32) — mechanism not captured yet

Phase	Mechanism	Company	Trial
Ph3	Quemliclustat, Placebo, Nab-paclitaxelunclassified	Arcus Biosciences, Inc.	NCT06608927
Ph2+Ph3	Navlimetostat, Gemcitabine, Nab-paclitaxelunclassified	Bristol-Myers Squibb	NCT07076121
Ph3	Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine, Ivon…unclassified	Akeso	NCT06953999
Ph3	Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; …unclassified	Jiangsu HengRui Medicine …	NCT07238283
Ph3	QLS31905, Nab-paclitaxel., Gemcitabineunclassified	Qilu Pharmaceutical Co., …	NCT07079228
Ph2+Ph3	SBP-101, Nab-paclitaxel, Gemcitabineunclassified	Panbela Therapeutics, Inc.	NCT05254171
Ph3	Liposomal Irinotecan, Oxaliplatin, S-1unclassified	CSPC Ouyi Pharmaceutical …	NCT06571461
Ph3	HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-pac…unclassified	Jiangsu HengRui Medicine …	NCT05751850
Ph3	Immuncell-LC, Gemcitabineunclassified	GC Cell Corporation	NCT04969731
Ph2+Ph3	DN022150+AG( Stage I ）, DN022150+AG（Stage II）, placebo+AG（Stage…unclassified	Jiangxi Kvvit Pharmaceuti…	NCT07656376
Ph1+Ph2	EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 …unclassified	Beijing Biotech	NCT07480928
Ph1+Ph2	AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, Cadonil…unclassified	Akeso	NCT06646055
Ph1+Ph2	E-EDV-D682, EDV-GC, Gemcitabineunclassified	Engeneic Pty Limited	NCT07049055
Ph1+Ph2	MR001, Irinotecan Liposome Injection combined with 5-FU/LV, Nab…unclassified	Shenzhen Majory Biotechno…	NCT07235202
Ph1+Ph2	RR001unclassified	EIR Biotherapies s.r.l.	NCT06861452
Ph2	N-803, Aldoxorubicin HCl, PD-L1 t-haNKunclassified	ImmunityBio, Inc.	NCT04390399
Ph1+Ph2	Spevatamig (PT886), Paclitaxel, Gemcitabineunclassified	Phanes Therapeutics	NCT05482893
Ph1+Ph2	Initial Feasibility Study to Treat Borderline Resectable Pancre…unclassified	CivaTech Oncology	NCT02843945
Ph2	TQB2916 Injection, Chemotherapyunclassified	Chia Tai Tianqing Pharmac…	NCT06962267
Ph1+Ph2	BEY1107unclassified	BeyondBio Inc.	NCT03579836
Ph1+Ph2	EF-009unclassified	Everfront Biotech Co., Lt…	NCT04381130
Ph1+Ph2	Gemcitabine, Nab paclitaxel, NLM-001unclassified	Nelum Corp	NCT04827953
Ph2	AK104, AK104, Gemcitabineunclassified	Akeso	NCT05859750
Ph1+Ph2	YL-13027, HY-0102, Gemcitabineunclassified	Shanghai YingLi Pharmaceu…	NCT06662669
Ph2	CEND-1, Gemcitabine, Nab paclitaxelunclassified	Qilu Pharmaceutical Co., …	NCT06261359
Ph2	HRS-7058unclassified	Shandong Suncadia Medicin…	NCT07589569
Ph1+Ph2	EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 …unclassified	Beijing Biotech	NCT07627711
Ph1	A First-in-Human Study to Evaluate Implantable Iontophoresis Ch…unclassified	Continuity Biosciences, L…	NCT07481383
Ph1	Systematic chemotherapyunclassified	NRT MedTech Australia Pty…	NCT07555587
Ph1	Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocar…unclassified	Impact Biotech Ltd	NCT05919238
Ph1	OMTX705, Nab-paclitaxel + Gemcitabine, Tislelizumab (i.v. 200mg)unclassified	Oncomatryx Biopharma S.L.	NCT07377045
Ph1	AK154, Cadonilimab, Ivonescimab (SMT112 or AK112) Injectionunclassified	Akeso	NCT06913218

Drugs in this landscape: zolbetuximab

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed

Revolution Medicines, Inc. 10 0 0

AstraZeneca 7 7 1

Astellas 7 1 0

Eli Lilly 4 7 1

Bristol-Myers Squibb 4 5 0

Seagen, a wholly owned subsidiary of Pfizer 4 0 2

Akeso 4 0 0

Novartis 3 5 5

Jiangsu HengRui Medicine Co., Ltd. 3 4 1

AbbVie 3 0 1

Qilu Pharmaceutical Co., Ltd. 3 1 0

CARsgen Therapeutics Co., Ltd. 3 1 0

Chipscreen Biosciences, Ltd. 3 0 0

Pfizer 2 5 5

ImmunityBio, Inc. 2 1 5

All 15 active Pancreatic Cancer sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2025 (154 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (93 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016

2017

2018

2019

2020

2021

102

2022

2023

116

2024

140

2025

154

2026

104

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (3)

140

2017 (3)

567

2018 (9)

218

2019 (5)

211

2020 (5)

2021 (5)

408

2022 (2)

556

2023 (8)

100

2024 (15)

210

2025 (24)

392

2026 (14)

399

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT06989437 RECRUITING

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Pfizer n=982

NCT06608927 ACTIVE NOT RECRUITING

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Arcus Biosciences, Inc. n=610

NCT07562152 RECRUITING

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Immuneering Corporation n=510

NCT07219238 RECRUITING

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

GE Healthcare n=175

NCT06958328 RECRUITING

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NRG Oncology n=356

NCT07252232 RECRUITING

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Revolution Medicines, Inc. n=500

NCT07076121 ACTIVE NOT RECRUITING

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Bristol-Myers Squibb n=470

NCT06625320 ACTIVE NOT RECRUITING

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Revolution Medicines, Inc. n=500

NCT07217717 RECRUITING

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

SOFIE n=200

NCT07409272 RECRUITING

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Astellas Pharma Global Development, Inc. n=614

NCT07491445 RECRUITING

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Revolution Medicines, Inc. n=900

NCT06998940 RECRUITING

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

SWOG Cancer Research Network n=94

NCT07490301 RECRUITING

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

AbbVie n=900

NCT06953999 RECRUITING

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

Akeso n=999

NCT07445295 NOT YET RECRUITING

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Chipscreen Biosciences, Ltd. n=558

NCT05836870 ACTIVE NOT RECRUITING

Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer

M.D. Anderson Cancer Center n=58

NCT07436741 NOT YET RECRUITING

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital n=106

NCT07429643 NOT YET RECRUITING

Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.

Assiut University n=20

NCT07044453 RECRUITING

Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

University Hospital, Rouen n=390

NCT04340141 ACTIVE NOT RECRUITING

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Alliance for Clinical Trials in Oncology n=358

NCT06752811 RECRUITING

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

Shanghai Yizhong Pharmaceutical Co., Ltd. n=416

NCT07383922 NOT YET RECRUITING

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

FutureGen Biopharmaceutical (Beijing) Co., Ltd n=524

NCT06861088 RECRUITING

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Quercis Pharma AG n=480

NCT07336953 NOT YET RECRUITING

A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

West China Hospital n=198

NCT06115499 ACTIVE NOT RECRUITING

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Alliance for Clinical Trials in Oncology n=10

NCT06361888 RECRUITING

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed n=502

NCT07165951 RECRUITING

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. n=566

NCT07272109 NOT YET RECRUITING

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

Fudan University n=210

NCT07238283 RECRUITING

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd. n=662

NCT06783140 ACTIVE NOT RECRUITING

Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

University Health Network, Toronto n=10

NCT07262567 RECRUITING

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Genfleet Therapeutics (Shanghai) Inc. n=320

NCT07232875 NOT YET RECRUITING

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd. n=588

NCT03257033 RECRUITING

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

RenovoRx n=190

NCT07079228 RECRUITING

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Qilu Pharmaceutical Co., Ltd. n=602

NCT07155525 RECRUITING

Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas

Minia University n=194

NCT07155629 NOT YET RECRUITING

Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer

Helsinki University Central Hospital n=381

NCT07081360 RECRUITING

Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer

Minia University n=262

NCT07138846 NOT YET RECRUITING

A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

Lepu Biopharma Co., Ltd. n=231

NCT07066098 RECRUITING

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

Innovent Biologics (Suzhou) Co. Ltd. n=201

NCT06018883 ACTIVE NOT RECRUITING

Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer

Fudan University n=100

NCT06095141 RECRUITING

Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

Fudan University n=30

NCT06250972 RECRUITING

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

Fudan University n=210

NCT07098598 RECRUITING

Pancreatic Cancer Diagnosis With FAPI-PET Imaging

Turku University Hospital n=100

NCT06999512 NOT YET RECRUITING

Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

Assistance Publique - Hôpitaux de Paris n=526

NCT06897644 RECRUITING

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Gruppo Oncologico del Nord-Ovest n=340

NCT05482516 RECRUITING

Evaluating Novel Therapies in ctDNA Positive GI Cancers

Georgetown University n=20

NCT06946420 ACTIVE NOT RECRUITING

SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=108

NCT05653453 RECRUITING

Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

Jiangsu Healthy Life Innovation Medical Technology Co., Ltd n=512

NCT03899636 ACTIVE NOT RECRUITING

A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

Angiodynamics, Inc. n=528

NCT06782412 RECRUITING

Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types

KU Leuven n=109

NCT06427447 RECRUITING

Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)

Changhai Hospital n=770

NCT01954992 RECRUITING

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Eleison Pharmaceuticals LLC. n=480

NCT05314998 NOT YET RECRUITING

Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

John Neoptolemos n=394

NCT06714604 RECRUITING

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

Sahlgrenska University Hospital n=432

NCT05529940 RECRUITING

NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Seoul National University Hospital n=609

NCT06601283 RECRUITING

Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer

Fudan University n=50

NCT06598033 RECRUITING

Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer

Fudan University n=50

NCT02919787 ACTIVE NOT RECRUITING

Nordic Pancreatic Cancer Trial (NorPACT) - 1

Oslo University Hospital n=140

NCT05254171 RECRUITING

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Panbela Therapeutics, Inc. n=600

NCT04927780 ACTIVE NOT RECRUITING

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Erasmus Medical Center n=378

NCT06571461 NOT YET RECRUITING

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

CSPC Ouyi Pharmaceutical Co., Ltd. n=408

NCT06079346 RECRUITING

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Oncotelic Inc. n=455

NCT06492941 NOT YET RECRUITING

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=142

NCT06409429 NOT YET RECRUITING

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital n=146

NCT05751850 RECRUITING

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd. n=778

NCT06391892 RECRUITING

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

Elisabethinen Hospital n=100

NCT06217042 NOT YET RECRUITING

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Fudan University n=524

NCT06017284 RECRUITING

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Fudan University n=100

NCT05268692 RECRUITING

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

Kochi University n=500

NCT04969731 RECRUITING

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

GC Cell Corporation n=408

NCT07621718 RECRUITING

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Revolution Medicines, Inc. n=670

NCT07632118 RECRUITING

Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery

Tianjin Medical University Cancer Institute and Hospital n=288

NCT07656376 NOT YET RECRUITING

Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

Jiangxi Kvvit Pharmaceutical Co., Ltd. n=465

NCT05131776 TERMINATED

EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma.

Chinese University of Hong Kong n=2

NCT01013649 COMPLETED

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

National Cancer Institute (NCI) n=546

NCT03943667 COMPLETED

Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

UNICANCER n=211

NCT03269994 COMPLETED

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Memorial Sloan Kettering Cancer Center n=967

NCT03434678 COMPLETED

Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection

Memorial Sloan Kettering Cancer Center n=133

NCT00806611 COMPLETED

Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University n=438

NCT03750669 COMPLETED

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University n=324

NCT01746979 COMPLETED

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

ImmunoGenesis n=693

NCT03468335 COMPLETED

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

AIO-Studien-gGmbH n=151

NCT03984214 COMPLETED

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

Arbeitsgemeinschaft medikamentoese Tumortherapie n=109

NCT04229004 COMPLETED

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Pancreatic Cancer Action Network n=502

NCT02457156 COMPLETED

Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy

University of Liverpool n=295

NCT02349412 COMPLETED

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

Alliance for Clinical Trials in Oncology n=405

NCT04935359 COMPLETED

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Novartis Pharmaceuticals n=511

NCT03512756 TERMINATED

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

Tyme, Inc n=130

NCT03941093 COMPLETED

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Kyntra Bio n=284

NCT01231347 COMPLETED

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

NantCell, Inc. n=800

NCT01827553 COMPLETED

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy

University of Erlangen-Nürnberg Medical School n=830

NCT02395016 COMPLETED

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Biotech Pharmaceutical Co., Ltd. n=90

NCT04300114 TERMINATED

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Jiangsu HengRui Medicine Co., Ltd. n=5

NCT02539537 COMPLETED

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

UNICANCER n=171

NCT04592861 TERMINATED

Carbon Ion RT for Locally Advanced Pancreatic Cancer

Albert Einstein College of Medicine n=5

NCT04329949 TERMINATED

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Corcept Therapeutics n=43

NCT05074589 COMPLETED

Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd. n=298

NCT02101021 TERMINATED

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Sierra Oncology LLC - a GSK company n=25

NCT03126435 COMPLETED

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

SynCore Biotechnology Co., Ltd. n=218

NCT02948309 COMPLETED

Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer

Karolinska University Hospital n=290

NCT03504423 COMPLETED

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Cornerstone Pharmaceuticals n=528

NCT01926197 COMPLETED

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

Stanford University n=27

NCT03665441 COMPLETED

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

ERYtech Pharma n=512

NCT01526135 COMPLETED

Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma

UNICANCER n=493

NCT03673137 COMPLETED

Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC

Fuda Cancer Hospital, Guangzhou n=120

NCT01956812 TERMINATED

Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

Gilead Sciences n=334

NCT03536182 WITHDRAWN

Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

University of Texas Southwestern Medical Center

NCT04151719 WITHDRAWN

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Bausch Health Americas, Inc.

NCT04083651 WITHDRAWN

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Bausch Health Americas, Inc.

NCT03649035 WITHDRAWN

Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma

Istituto Clinico Humanitas

NCT02195232 COMPLETED

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

Jeffrey Zwicker, MD n=64

NCT02436668 COMPLETED

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Pharmacyclics LLC. n=430

NCT03766295 COMPLETED

Masitinib Plus Gemcitabine in Pancreatic Cancer

AB Science n=377

NCT02340728 COMPLETED

Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies

Memorial Sloan Kettering Cancer Center n=24

NCT02923921 COMPLETED

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company n=567

NCT01072981 COMPLETED

Immunotherapy Study for Surgically Resected Pancreatic Cancer

NewLink Genetics Corporation n=722

NCT01836432 TERMINATED

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NewLink Genetics Corporation n=302

NCT01438476 COMPLETED

Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas

M.D. Anderson Cancer Center n=178

NCT00844649 COMPLETED

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Celgene n=861

NCT01314027 TERMINATED

Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer

University of Zurich n=38

NCT02404363 TERMINATED

Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy

Assistance Publique - Hôpitaux de Paris n=39

NCT02117479 TERMINATED

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Incyte Corporation n=321

NCT03239184 COMPLETED

Bioinformation Therapy for Pancreatic Cancer

Fuda Cancer Hospital, Guangzhou n=120

NCT00789633 COMPLETED

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

AB Science n=353

NCT01900327 TERMINATED

Neoadjuvant Treatment in Resectable Pancreatic Cancer

Universitätsklinikum Hamburg-Eppendorf n=32

NCT01458717 COMPLETED

Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

Seoul National University Hospital n=58

NCT02284139 COMPLETED

Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects

Dong-A University Hospital n=90

NCT02119663 TERMINATED

A Study of Ruxolitinib in Pancreatic Cancer Patients

Incyte Corporation n=86

NCT02988635 COMPLETED

Early Palliative Care on Quality of Life of Advanced Cancer Patients

Azienda Ospedaliero-Universitaria di Parma n=281

NCT01360853 COMPLETED

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Traws Pharma, Inc. n=160

NCT01494506 COMPLETED

Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals n=417

NCT00994110 COMPLETED

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Memorial Sloan Kettering Cancer Center n=439

NCT00634725 COMPLETED

Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

GERCOR - Multidisciplinary Oncology Cooperative Group n=820

NCT01598584 WITHDRAWN

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT01419002 TERMINATED

Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer

CHIR-Net n=5

NCT01362582 TERMINATED

Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer

National Center for Tumor Diseases, Heidelberg n=32

NCT04172532 RECRUITING

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

National Cancer Institute (NCI)

NCT05554367 ACTIVE NOT RECRUITING

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

NCT04548752 ACTIVE NOT RECRUITING

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

National Cancer Institute (NCI)

NCT04550494 RECRUITING

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

NCT07578337 NOT YET RECRUITING

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

Nelum Corp

NCT04858334 RECRUITING

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

National Cancer Institute (NCI)

NCT01972919 ACTIVE NOT RECRUITING

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

Medical College of Wisconsin

NCT07529808 NOT YET RECRUITING

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

BigHat Biosciences, Inc.

NCT01174121 RECRUITING

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

National Cancer Institute (NCI)

NCT07575191 RECRUITING

Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer

Smartwise Sweden AB

NCT05922930 RECRUITING

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

M.D. Anderson Cancer Center

NCT04083599 ACTIVE NOT RECRUITING

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

NCT03523312 ACTIVE NOT RECRUITING

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT06239194 RECRUITING

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

NCT04789486 RECRUITING

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Dana-Farber Cancer Institute

NCT06094140 ACTIVE NOT RECRUITING

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Australasian Gastro-Intestinal Trials Group

NCT03652428 RECRUITING

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

University of Maryland, Baltimore

NCT07076212 RECRUITING

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Medical University of South Carolina

NCT06941857 RECRUITING

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT07026279 ACTIVE NOT RECRUITING

A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

Amplia Therapeutics Limited

NCT04851119 RECRUITING

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

NCT04233866 ACTIVE NOT RECRUITING

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

ECOG-ACRIN Cancer Research Group

NCT06503146 RECRUITING

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Cancer Institute (NCI)

NCT07565155 NOT YET RECRUITING

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

Peter Hosein, MD

NCT06015659 ACTIVE NOT RECRUITING

ZN-c3 + Gemcitabine in Pancreatic Cancer

Brandon Huffman, MD

NCT07563738 RECRUITING

A 2-part Phase 1/2 Open-label Trial on ODM-212

Orion Corporation, Orion Pharma

NCT04421820 RECRUITING

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

NCT05933265 ACTIVE NOT RECRUITING

Study of LP-184 in Patients With Advanced Solid Tumors

Lantern Pharma Inc.

NCT07561463 NOT YET RECRUITING

Sacituzumab Tirumotecan for Pancreatic Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT02498613 ACTIVE NOT RECRUITING

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

NCT07157033 RECRUITING

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Xerient Pharma

NCT06305247 ACTIVE NOT RECRUITING

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Ipsen

NCT06710756 RECRUITING

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Perspective Therapeutics

NCT07478523 RECRUITING

FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers

University Hospital, Bordeaux

NCT07214298 RECRUITING

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Roswell Park Cancer Institute

NCT04887805 ACTIVE NOT RECRUITING

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

City of Hope Medical Center

NCT06710132 ACTIVE NOT RECRUITING

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

EMD Serono Research & Development Institute, Inc.

NCT07255404 RECRUITING

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

BioNTech SE

NCT06844422 RECRUITING

Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)

Shandong Cancer Hospital and Institute

NCT05988918 ACTIVE NOT RECRUITING

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

University of Michigan Rogel Cancer Center

NCT03190941 RECRUITING

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

National Cancer Institute (NCI)

NCT05985655 RECRUITING

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

NCT06128551 RECRUITING

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Revolution Medicines, Inc.

NCT03682289 ACTIVE NOT RECRUITING

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Rahul Aggarwal

NCT06483555 RECRUITING

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

UNC Lineberger Comprehensive Cancer Center

NCT06921928 RECRUITING

Study for AZD4360 in Participants With Advanced Solid Tumours

AstraZeneca

NCT07450859 RECRUITING

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

BicycleTx Limited

NCT06423326 RECRUITING

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Emory University

NCT07020221 RECRUITING

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Verastem, Inc.

NCT06922591 RECRUITING

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Tango Therapeutics, Inc.

NCT07542002 RECRUITING

Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study

Ningbo Medical Center Lihuili Hospital

NCT07539155 NOT YET RECRUITING

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

University of Arkansas

NCT03301805 NOT YET RECRUITING

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer

Rgene Corporation

NCT05632328 ACTIVE NOT RECRUITING

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Bruno Bockorny

NCT03485209 ACTIVE NOT RECRUITING

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT07444541 NOT YET RECRUITING

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Anova Innovation Limited

NCT04940286 ACTIVE NOT RECRUITING

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

M.D. Anderson Cancer Center

NCT06453486 RECRUITING

A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

University Health Network, Toronto

NCT07283705 RECRUITING

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

M.D. Anderson Cancer Center

NCT07488676 RECRUITING

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Astellas Pharma Global Development, Inc.

NCT07126158 RECRUITING

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Washington University School of Medicine

NCT06659705 RECRUITING

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

Institut Curie

NCT07353645 RECRUITING

KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT05065801 RECRUITING

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

Institut du Cancer de Montpellier - Val d'Aurelle

NCT07438106 RECRUITING

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

NCT04895709 RECRUITING

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

NCT07223047 RECRUITING

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Bristol-Myers Squibb

NCT07114861 RECRUITING

The KN510713 Study in Combination With mFOLFIRINOX

New Cancer Cure-Bio Co.,Ltd.

NCT05257993 RECRUITING

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Onconic Therapeutics Inc.

NCT05053971 RECRUITING

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

National Cancer Institute (NCI)

NCT05077800 ACTIVE NOT RECRUITING

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Colin D. Weekes, M.D., PhD

NCT06790602 RECRUITING

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

University of California, San Diego

NCT05945823 ACTIVE NOT RECRUITING

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

NCT06695845 RECRUITING

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

NCT05624918 RECRUITING

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Ashish Manne

NCT02830724 RECRUITING

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

National Cancer Institute (NCI)

NCT03678883 ACTIVE NOT RECRUITING

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

NCT06850623 RECRUITING

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

EXACT Therapeutics AS

NCT04820179 ACTIVE NOT RECRUITING

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

University of Arizona

NCT06445062 RECRUITING

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Revolution Medicines, Inc.

NCT06821997 RECRUITING

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

Roswell Park Cancer Institute

NCT07504263 NOT YET RECRUITING

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

Recurv Pharma Inc

NCT07504471 RECRUITING

Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases

Ruijin Hospital

NCT06904378 RECRUITING

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

NCT07483983 RECRUITING

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

Gustave Roussy, Cancer Campus, Grand Paris

NCT07432633 RECRUITING

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Blue Earth Diagnostics

NCT05825066 RECRUITING

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Wake Forest University Health Sciences

NCT07483554 RECRUITING

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

NCT07480928 RECRUITING

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Beijing Biotech

NCT07163273 RECRUITING

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

Northwell Health

NCT06412510 RECRUITING

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

Case Comprehensive Cancer Center

NCT04657068 RECRUITING

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Artios Pharma Ltd

NCT06244771 RECRUITING

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Frontier Medicines Corporation

NCT06492915 ACTIVE NOT RECRUITING

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Chipscreen Biosciences, Ltd.

NCT03384238 RECRUITING

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

George Poultsides

NCT05726864 ACTIVE NOT RECRUITING

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Elicio Therapeutics

NCT07477418 NOT YET RECRUITING

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

University of Vermont

NCT06756074 RECRUITING

Reinforced Pancreaticojejunostomy With or Without glubran2

Minia University

NCT07475234 NOT YET RECRUITING

Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma

Xiuchao Wang

NCT06479239 RECRUITING

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

University of Virginia

NCT07469956 NOT YET RECRUITING

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Sun Yat-sen University

NCT06008288 RECRUITING

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Allist Pharmaceuticals, Inc.

NCT03816163 ACTIVE NOT RECRUITING

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Astellas Pharma Global Development, Inc.

NCT07435038 NOT YET RECRUITING

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Betta Pharmaceuticals Co., Ltd.

NCT06821503 RECRUITING

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT06646055 ACTIVE NOT RECRUITING

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Akeso

NCT07199764 RECRUITING

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

University of Pennsylvania

NCT02568267 ACTIVE NOT RECRUITING

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Hoffmann-La Roche

NCT06895031 RECRUITING

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Guangzhou JOYO Pharma Co., Ltd

NCT04683315 RECRUITING

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Medical College of Wisconsin

NCT07114315 RECRUITING

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

Akeso

NCT07446270 NOT YET RECRUITING

Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

Chinese PLA General Hospital

NCT07049055 RECRUITING

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Engeneic Pty Limited

NCT06048484 RECRUITING

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Gulam Manji

NCT03483038 ACTIVE NOT RECRUITING

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

University of Florida

NCT07006077 RECRUITING

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

Hangzhou Converd Co., Ltd.

NCT05642962 ACTIVE NOT RECRUITING

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Memorial Sloan Kettering Cancer Center

NCT04605913 RECRUITING

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Mayo Clinic

NCT06005493 RECRUITING

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

AstraZeneca

NCT04644068 ACTIVE NOT RECRUITING

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

AstraZeneca

NCT07410676 RECRUITING

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Essen Biotech

NCT04666740 ACTIVE NOT RECRUITING

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

Memorial Sloan Kettering Cancer Center

NCT07030257 RECRUITING

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Tasca Therapeutics

NCT05000294 RECRUITING

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

NCT07410494 RECRUITING

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Essen Biotech

NCT07415525 NOT YET RECRUITING

IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

Zhejiang University

NCT06906562 RECRUITING

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Sameek Roychowdhury

NCT07240766 RECRUITING

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Zhejiang University

NCT06384560 RECRUITING

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Amsterdam UMC, location VUmc

NCT05466799 ACTIVE NOT RECRUITING

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

OncoSil Medical Limited

NCT05558982 ACTIVE NOT RECRUITING

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Georgetown University

NCT06219941 RECRUITING

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

AstraZeneca

NCT04115163 RECRUITING

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Anne Noonan

NCT05908747 ACTIVE NOT RECRUITING

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT03851614 ACTIVE NOT RECRUITING

Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors

University Health Network, Toronto

NCT06662006 RECRUITING

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT07386704 ENROLLING BY INVITATION

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Peking University First Hospital

NCT06381154 ACTIVE NOT RECRUITING

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Mayo Clinic

NCT07377526 RECRUITING

Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

M.D. Anderson Cancer Center

NCT07148128 RECRUITING

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Auricula Biosciences Inc.

NCT06951997 RECRUITING

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT07312422 RECRUITING

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Zhejiang Provincial People's Hospital

NCT04098237 ACTIVE NOT RECRUITING

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

Andrew Hendifar, MD

NCT06428409 RECRUITING

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Merck Sharp & Dohme LLC

NCT02584244 RECRUITING

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

Lumicell, Inc.

NCT06168812 ACTIVE NOT RECRUITING

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT07342725 NOT YET RECRUITING

Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Ruijin Hospital

NCT05688215 RECRUITING

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Jonsson Comprehensive Cancer Center

NCT07344220 ENROLLING BY INVITATION

Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

Hoag Memorial Hospital Presbyterian

NCT04539808 ACTIVE NOT RECRUITING

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

NCT07296341 RECRUITING

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

NCT06334432 ACTIVE NOT RECRUITING

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Nuvation Bio Inc.

NCT03977233 RECRUITING

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

UNC Lineberger Comprehensive Cancer Center

NCT05651022 ACTIVE NOT RECRUITING

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Indaptus Therapeutics, Inc

NCT03104439 ACTIVE NOT RECRUITING

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Massachusetts General Hospital

NCT07333287 NOT YET RECRUITING

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

Shandong Provincial Hospital

NCT03322995 RECRUITING

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

Medical College of Wisconsin

NCT06399757 RECRUITING

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Apollo Therapeutics Ltd

NCT04241276 ACTIVE NOT RECRUITING

A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer

Queen Mary University of London

NCT06547736 RECRUITING

Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

Fudan University

NCT07131514 RECRUITING

HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Ruijin Hospital

NCT07110064 RECRUITING

QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Du Juan

NCT07235202 RECRUITING

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

Shenzhen Majory Biotechnology Co., Ltd.

NCT07306286 RECRUITING

Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

Ruijin Hospital

NCT07306273 RECRUITING

IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

Ruijin Hospital

NCT06861452 RECRUITING

Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

EIR Biotherapies s.r.l.

NCT04146298 RECRUITING

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Changhai Hospital

NCT03991962 ACTIVE NOT RECRUITING

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma

Yale University

NCT07301229 NOT YET RECRUITING

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer

Shanghai Henlius Biotech

NCT07303465 RECRUITING

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Ranok Therapeutics (Hangzhou) Co., Ltd.

NCT07226856 RECRUITING

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Mayo Clinic

NCT05249101 ACTIVE NOT RECRUITING

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

CG Pharmaceuticals, Inc

NCT04396821 ACTIVE NOT RECRUITING

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Suzhou Transcenta Therapeutics Co., Ltd.

NCT02955940 ACTIVE NOT RECRUITING

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Incyte Corporation

NCT07284277 RECRUITING

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

Clinica Universidad de Navarra, Universidad de Navarra

NCT04858009 RECRUITING

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

Mayo Clinic

NCT04390399 ACTIVE NOT RECRUITING

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

ImmunityBio, Inc.

NCT07280377 ACTIVE NOT RECRUITING

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Oncolytics Biotech

NCT03556228 RECRUITING

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

VM Oncology, LLC

NCT07277452 NOT YET RECRUITING

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

NCT06943521 RECRUITING

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America, Inc.

NCT06584227 RECRUITING

Adebrelimab and Chidamide for Pancreatic Cancer

Liu Xiufeng

NCT07269626 RECRUITING

PULSAR in Systemic Therapy for Pancreatic Cancer

Samsung Medical Center

NCT02481635 ACTIVE NOT RECRUITING

A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer

University Health Network, Toronto

NCT04570943 RECRUITING

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

NCT04753879 ACTIVE NOT RECRUITING

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02451982 ACTIVE NOT RECRUITING

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06782932 RECRUITING

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06333314 RECRUITING

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

UNICANCER

NCT03608631 RECRUITING

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

M.D. Anderson Cancer Center

NCT07233850 NOT YET RECRUITING

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

Shenyang Sunshine Pharmaceutical Co., LTD.

NCT06177522 NOT YET RECRUITING

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Jinling Hospital, China

NCT05438459 RECRUITING

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

Kyushu University

NCT07230301 NOT YET RECRUITING

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

Sizhen Wang

NCT06773130 ACTIVE NOT RECRUITING

HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

West China Hospital

NCT05360732 ACTIVE NOT RECRUITING

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Fox Chase Cancer Center

NCT05379985 RECRUITING

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Revolution Medicines, Inc.

NCT04926467 RECRUITING

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

Baylor Research Institute

NCT06576115 RECRUITING

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Barbara Ann Karmanos Cancer Institute

NCT05482893 RECRUITING

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Phanes Therapeutics

NCT04821284 ACTIVE NOT RECRUITING

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Flemming Forsberg

NCT03080974 RECRUITING

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

University of Louisville

NCT05706129 RECRUITING

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

ITM Oncologics GmbH

NCT04888312 ACTIVE NOT RECRUITING

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

Alligator Bioscience AB

NCT03245541 ACTIVE NOT RECRUITING

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT07208539 NOT YET RECRUITING

AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.

Shanghai Zhongshan Hospital

NCT03915678 RECRUITING

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Institut Bergonié

NCT03492671 RECRUITING

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Loma Linda University

NCT05518903 RECRUITING

Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma

Mayo Clinic

NCT03563248 ACTIVE NOT RECRUITING

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Massachusetts General Hospital

NCT07096362 RECRUITING

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

University of Miami

NCT05093231 RECRUITING

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Cambridge University Hospitals NHS Foundation Trust

NCT06747845 RECRUITING

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Abramson Cancer Center at Penn Medicine

NCT07175389 NOT YET RECRUITING

JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure

West China Hospital

NCT07173387 ACTIVE NOT RECRUITING

Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer

Shandong Cancer Hospital and Institute

NCT07172802 RECRUITING

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

GI Innovation, Inc.

NCT06831136 RECRUITING

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

The University of Texas Health Science Center, Houston

NCT02598349 RECRUITING

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

Proton Collaborative Group

NCT06313970 RECRUITING

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Fudan University

NCT05585320 ACTIVE NOT RECRUITING

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Immuneering Corporation

NCT05451849 ACTIVE NOT RECRUITING

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

NCT01088789 ACTIVE NOT RECRUITING

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06587061 RECRUITING

HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Ruijin Hospital

NCT04111172 ACTIVE NOT RECRUITING

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

Thomas Jefferson University

NCT06758544 RECRUITING

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer

Guangdong Provincial People's Hospital

NCT05864144 ACTIVE NOT RECRUITING

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

NCT04669197 ACTIVE NOT RECRUITING

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

HonorHealth Research Institute

NCT06843551 RECRUITING

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

Benjamin Spieler

NCT06298916 RECRUITING

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

Lantheus Medical Imaging

NCT05057013 ACTIVE NOT RECRUITING

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Cancer Research UK

NCT06196671 NOT YET RECRUITING

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Fudan University

NCT06149689 RECRUITING

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer

Fudan University

NCT07108504 NOT YET RECRUITING

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Shanghai Zhongshan Hospital

NCT07101679 RECRUITING

A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer

West China Hospital

NCT06249321 RECRUITING

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy

Fudan University

NCT07097064 NOT YET RECRUITING

Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers

Institut du Cancer de Montpellier - Val d'Aurelle

NCT06105021 ACTIVE NOT RECRUITING

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Affini-T Therapeutics, Inc.

NCT05969171 RECRUITING

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Fudan University

NCT06605430 RECRUITING

Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer

HealthPartners Institute

NCT06015724 RECRUITING

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Georgetown University

NCT03806309 ACTIVE NOT RECRUITING

OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

GERCOR - Multidisciplinary Oncology Cooperative Group

NCT04348045 ACTIVE NOT RECRUITING

Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.

GERCOR - Multidisciplinary Oncology Cooperative Group

NCT05604560 ACTIVE NOT RECRUITING

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Lei Zheng

NCT06024824 RECRUITING

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)

Cancer Trials Ireland

NCT05132504 RECRUITING

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Baylor College of Medicine

NCT07066995 RECRUITING

Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

Essen Biotech

NCT03935893 ACTIVE NOT RECRUITING

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Udai Kammula

NCT04098081 ACTIVE NOT RECRUITING

1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

University of Maryland, Baltimore

NCT07028424 NOT YET RECRUITING

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

GERCOR - Multidisciplinary Oncology Cooperative Group

NCT06825546 RECRUITING

Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

Sir Run Run Shaw Hospital

NCT03175224 RECRUITING

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Apollomics Inc.

NCT04901741 NOT YET RECRUITING

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

TME Pharma AG

NCT07040228 RECRUITING

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

Junjie Hang

NCT05451043 RECRUITING

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

AHS Cancer Control Alberta

NCT06435260 RECRUITING

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

Hebei Medical University Fourth Hospital

NCT04543071 RECRUITING

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Gulam Manji

NCT06135896 RECRUITING

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

National Cancer Center, Korea

NCT02843945 RECRUITING

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

CivaTech Oncology

NCT03856658 ACTIVE NOT RECRUITING

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

Corewell Health West

NCT05929885 RECRUITING

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

National Cancer Centre, Singapore

NCT04581473 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

CARsgen Therapeutics Co., Ltd.

NCT05851924 RECRUITING

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Memorial Sloan Kettering Cancer Center

NCT05141149 RECRUITING

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

Prestige Biopharma Limited

NCT06199895 RECRUITING

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

Liu Huang

NCT06944106 RECRUITING

A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT04084496 RECRUITING

mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients

Sun Yat-sen University

NCT02340117 ACTIVE NOT RECRUITING

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

SynerGene Therapeutics, Inc.

NCT06991491 NOT YET RECRUITING

Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)

West China Hospital

NCT03073785 ACTIVE NOT RECRUITING

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

University of Nebraska

NCT05827055 ACTIVE NOT RECRUITING

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Georgetown University

NCT05102721 ACTIVE NOT RECRUITING

Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

Vaccinex Inc.

NCT04990609 RECRUITING

EUS-RFA PANCARDINAL-1 Trial

The University of Texas Health Science Center, Houston

NCT06962267 RECRUITING

A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

NCT02983578 ACTIVE NOT RECRUITING

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

M.D. Anderson Cancer Center

NCT04503265 RECRUITING

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AtlasMedx, Incorporated

NCT05827796 RECRUITING

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

InxMed (Shanghai) Co., Ltd.

NCT02912949 ACTIVE NOT RECRUITING

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Partner Therapeutics, Inc.

NCT06946901 RECRUITING

The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial

Shanghai Zhongshan Hospital

NCT05736731 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

A2 Biotherapeutics Inc.

NCT06938282 NOT YET RECRUITING

An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

Shanghai Zhongshan Hospital

NCT06938503 NOT YET RECRUITING

AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT05915351 ACTIVE NOT RECRUITING

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

University of Kansas Medical Center

NCT06916975 NOT YET RECRUITING

Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Jin Xu

NCT05776524 RECRUITING

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

THERABIONIC INC.

NCT06888674 NOT YET RECRUITING

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Zhejiang University

NCT06888648 NOT YET RECRUITING

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Zhejiang University

NCT04802876 ACTIVE NOT RECRUITING

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

SOLTI Breast Cancer Research Group

NCT01585805 ACTIVE NOT RECRUITING

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

NCT06868849 RECRUITING

A Study of JMT203 in Patients With Cancer Cachexia

Shanghai JMT-Bio Inc.

NCT03579836 RECRUITING

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

BeyondBio Inc.

NCT06866977 NOT YET RECRUITING

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer

Xiangya Hospital of Central South University

NCT04825288 ACTIVE NOT RECRUITING

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

XBiotech, Inc.

NCT04381130 NOT YET RECRUITING

A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer

Everfront Biotech Co., Ltd.

NCT05927142 RECRUITING

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Joachim Aerts, MD PhD

NCT06816914 RECRUITING

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

Taichung Veterans General Hospital

NCT06819215 RECRUITING

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

NCT06750861 NOT YET RECRUITING

QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT06792435 RECRUITING

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

Evopoint Biosciences Inc.

NCT06736717 RECRUITING

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

University of Kansas Medical Center

NCT05472259 RECRUITING

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

Belgian Group of Digestive Oncology

NCT05355298 ACTIVE NOT RECRUITING

ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

Amplia Therapeutics Limited

NCT05431270 RECRUITING

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phanes Therapeutics

NCT06387342 RECRUITING

Namodenoson Treatment of Advanced Pancreatic Cancer

Can-Fite BioPharma

NCT06789679 RECRUITING

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT04986930 ACTIVE NOT RECRUITING

mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma

Asan Medical Center

NCT05562297 NOT YET RECRUITING

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Shanghai Zhongshan Hospital

NCT06782555 RECRUITING

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

ImmunoGenesis

NCT06782685 RECRUITING

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

Dai, Guanghai

NCT06766019 ACTIVE NOT RECRUITING

Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

NCT04404595 ACTIVE NOT RECRUITING

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

CARsgen Therapeutics Co., Ltd.

NCT06761027 RECRUITING

mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer

Fujian Provincial Hospital

NCT03368963 ACTIVE NOT RECRUITING

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Emory University

NCT05218889 RECRUITING

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Chinese PLA General Hospital

NCT04827953 ACTIVE NOT RECRUITING

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Nelum Corp

NCT06405490 RECRUITING

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT05859750 RECRUITING

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Akeso

NCT06722911 RECRUITING

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Zhejiang Provincial People's Hospital

NCT06472037 RECRUITING

AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC

Tianjin Medical University Cancer Institute and Hospital

NCT06700603 NOT YET RECRUITING

Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

Rui-hua Xu, MD, PhD

NCT06690528 RECRUITING

Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver

Azienda Ospedaliera di Padova

NCT06598007 RECRUITING

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

Crossignal Therapeutics, Inc.

NCT06669078 NOT YET RECRUITING

NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT06389760 RECRUITING

Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT06662669 NOT YET RECRUITING

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Shanghai YingLi Pharmaceutical Co. Ltd.

NCT05659914 ACTIVE NOT RECRUITING

Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

NCT05462496 RECRUITING

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Icahn School of Medicine at Mount Sinai

NCT05620134 ACTIVE NOT RECRUITING

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Salubris Biotherapeutics Inc

NCT04452461 RECRUITING

Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

Hamilton Health Sciences Corporation

NCT04913337 ACTIVE NOT RECRUITING

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

NCT06621095 NOT YET RECRUITING

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

RenJi Hospital

NCT04205227 ACTIVE NOT RECRUITING

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

ENB Therapeutics, Inc

NCT06261359 RECRUITING

A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma

Qilu Pharmaceutical Co., Ltd.

NCT06224387 RECRUITING

CTS2190 Phase I /II Clinical Study in Patients

CytosinLab Therapeutics Co., Ltd.

NCT06475326 RECRUITING

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

Fudan University

NCT06427239 RECRUITING

Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Fudan University

NCT06531278 RECRUITING

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

Jiang Long

NCT06513455 NOT YET RECRUITING

Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

Harbin Medical University

NCT06387810 RECRUITING

Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer

Peking Union Medical College Hospital

NCT06491472 RECRUITING

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06454448 RECRUITING

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT06359275 RECRUITING

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Fudan University

NCT06467565 RECRUITING

NALIRIFOX as Induction Therapy in LAPC

The First Affiliated Hospital with Nanjing Medical University

NCT05766748 RECRUITING

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Cantex Pharmaceuticals

NCT06018896 RECRUITING

Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer

Fudan University

NCT06436976 RECRUITING

The Effect of Probiotics ATG-F4 in Cancer Patients

Chungnam National University Hospital

NCT06429904 ACTIVE NOT RECRUITING

Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

Peking Union Medical College Hospital

NCT06427460 RECRUITING

Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)

Changhai Hospital

NCT06422156 NOT YET RECRUITING

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Peking University Third Hospital

NCT03337087 ACTIVE NOT RECRUITING

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Academic and Community Cancer Research United

NCT04672005 ACTIVE NOT RECRUITING

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

Lyudmyla Berim

NCT06404840 RECRUITING

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Tianjin Medical University Cancer Institute and Hospital

NCT03351296 ACTIVE NOT RECRUITING

Two Chemotherapy Regimens Plus or Minus Bevacizumab

Gustave Roussy, Cancer Campus, Grand Paris

NCT06329947 NOT YET RECRUITING

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Rui-hua Xu, MD, PhD

NCT06078787 RECRUITING

Olaparib in PALB2 Advanced Pancreatic Cancer

Azienda Ospedaliero-Universitaria di Modena

NCT04589234 ACTIVE NOT RECRUITING

Saltikva for Metastatic Pancreatic Cancer

Salspera LLC

NCT06370754 NOT YET RECRUITING

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Fudan University

NCT06361030 NOT YET RECRUITING

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06111274 RECRUITING

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Abbisko Therapeutics Co, Ltd

NCT06345599 NOT YET RECRUITING

PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

Second Affiliated Hospital of Soochow University

NCT06145074 RECRUITING

Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.

Zealand University Hospital

NCT06196788 RECRUITING

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Fudan University

NCT06259058 NOT YET RECRUITING

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT06233877 NOT YET RECRUITING

Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer

Hirschfeld Oncology

NCT06151262 RECRUITING

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT05988814 RECRUITING

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Centre Georges Francois Leclerc

NCT06245330 RECRUITING

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

Ascentawits Pharmaceuticals, Ltd

NCT06234072 NOT YET RECRUITING

Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients

Shenzhen University General Hospital

NCT06210360 NOT YET RECRUITING

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Changhai Hospital

NCT06060405 RECRUITING

Durvalumab and Oleclumab in Resectable PDAC

University Health Network, Toronto

NCT02446093 ACTIVE NOT RECRUITING

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Candel Therapeutics, Inc.

NCT06172036 NOT YET RECRUITING

Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab

Zhejiang University

NCT06159478 RECRUITING

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

National Cancer Center, Japan

NCT06166589 NOT YET RECRUITING

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Shanghai Zhongshan Hospital

NCT05810792 NOT YET RECRUITING

Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

Sahlgrenska University Hospital

NCT05637567 NOT YET RECRUITING

Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head

German Cancer Research Center

NCT05988372 NOT YET RECRUITING

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

Sun Yat-sen University

NCT06051851 RECRUITING

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT06009029 NOT YET RECRUITING

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Peking University Third Hospital

NCT05083247 RECRUITING

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Erasme University Hospital

NCT05733000 RECRUITING

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

NCT05679583 RECRUITING

Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer

Yonsei University

NCT04361162 ACTIVE NOT RECRUITING

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

Massachusetts General Hospital

NCT03498326 RECRUITING

Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT07600268 RECRUITING

Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer

Shandong Cancer Hospital and Institute

NCT07595835 RECRUITING

CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer

M.R. Meijerink

NCT07594626 NOT YET RECRUITING

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

Northwestern University

NCT07595172 RECRUITING

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

West China Hospital

NCT07589569 RECRUITING

An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

Shandong Suncadia Medicine Co., Ltd.

NCT07586813 RECRUITING

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors

Peking University People's Hospital

NCT07610798 RECRUITING

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Shenzhen Ionova Life Sciences Co., Ltd.

NCT07629960 RECRUITING

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Blueprint Medicines Corporation

NCT07629609 RECRUITING

BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

Barbara Malene Fischer

NCT07627711 RECRUITING

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Beijing Biotech

NCT07623642 NOT YET RECRUITING

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

GV20 Therapeutics

NCT07619521 NOT YET RECRUITING

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

National Cancer Institute (NCI)

NCT07616362 NOT YET RECRUITING

Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.

Federation Francophone de Cancerologie Digestive

NCT07644559 RECRUITING

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Verastem, Inc.

NCT07640295 NOT YET RECRUITING

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

Jacobio Pharmaceuticals Co., Ltd.

NCT07670312 NOT YET RECRUITING

Evaluation of XYA02 in Patients With Advanced Solid Tumors

XYone Therapeutics, Inc

NCT07665684 NOT YET RECRUITING

Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer

University Health Network, Toronto

NCT06119217 COMPLETED

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics, Inc.

NCT03415854 COMPLETED

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

HonorHealth Research Institute

NCT03767582 COMPLETED

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05415917 WITHDRAWN

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

Rutgers, The State University of New Jersey

NCT03797326 COMPLETED

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Merck Sharp & Dohme LLC

NCT04481204 WITHDRAWN

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

NCT06390059 COMPLETED

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

NovoCure Ltd.

NCT06630325 TERMINATED

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

NCT05014776 COMPLETED

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03915444 COMPLETED

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

HonorHealth Research Institute

NCT03138720 COMPLETED

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

HonorHealth Research Institute

NCT04387071 TERMINATED

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

University of Southern California

NCT05518110 TERMINATED

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Cancer Trials Ireland

NCT02985125 COMPLETED

LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Georgetown University

NCT02077881 COMPLETED

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

NewLink Genetics Corporation

NCT05586516 COMPLETED

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

iOnctura

NCT03601923 COMPLETED

Niraparib in Patients With Pancreatic Cancer

Dana-Farber Cancer Institute

NCT05039177 COMPLETED

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Erasca, Inc.

NCT06538623 COMPLETED

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

Ruijin Hospital

NCT03745326 TERMINATED

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

National Cancer Institute (NCI)

NCT02648282 COMPLETED

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01204372 COMPLETED

Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma

Institut du Cancer de Montpellier - Val d'Aurelle

NCT04332653 COMPLETED

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

NCT02047474 COMPLETED

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Yale University

NCT04705818 COMPLETED

Combining Epigenetic And Immune Therapy to Beat Cancer.

Institut Bergonié

NCT02890355 COMPLETED

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

NCT04975516 TERMINATED

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

Mayo Clinic

NCT02705196 COMPLETED

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Lokon Pharma AB

NCT05419479 SUSPENDED

Switch Maintenance in Pancreatic

James Cleary, MD, PhD

NCT04426669 COMPLETED

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Intima Bioscience, Inc.

NCT03785210 TERMINATED

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

National Cancer Institute (NCI)

NCT04469556 COMPLETED

Pancreatic Adenocarcinoma Signature Stratification for Treatment

University Health Network, Toronto

NCT05442749 TERMINATED

Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer

Centre Leon Berard

NCT03983057 COMPLETED

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Zhejiang University

NCT03727880 COMPLETED

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Lei Zheng

NCT04524702 COMPLETED

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Emory University

NCT05262855 COMPLETED

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

SOFIE

NCT05641896 COMPLETED

Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

SOFIE

NCT05070247 TERMINATED

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Takeda

NCT06478862 TERMINATED

Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy

Lipomedix Pharmaceuticals Inc.

NCT04643405 TERMINATED

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Ascentage Pharma Group Inc.

NCT03443492 COMPLETED

SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer

National Health Research Institutes, Taiwan

NCT04752696 COMPLETED

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Cardiff Oncology

NCT03910387 COMPLETED

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Emory University

NCT05289830 TERMINATED

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Case Comprehensive Cancer Center

NCT05114213 TERMINATED

MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC

Ludwig-Maximilians - University of Munich

NCT04779151 TERMINATED

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

Gustave Roussy, Cancer Campus, Grand Paris

NCT05795595 COMPLETED

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

CRISPR Therapeutics AG

NCT03193190 COMPLETED

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

NCT04054362 COMPLETED

Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Barts & The London NHS Trust

NCT05052723 COMPLETED

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Joseph Kim

NCT07026916 WITHDRAWN

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Genfleet Therapeutics (Shanghai) Inc.

NCT05525286 TERMINATED

Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma

SOTIO Biotech a.s.

NCT04844970 TERMINATED

Anamorelin Study for Advanced Pancreatic Cancer

Lahey Clinic

NCT05630183 COMPLETED

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Agenus Inc.

NCT04504916 TERMINATED

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT05194735 TERMINATED

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Alaunos Therapeutics

NCT01489865 COMPLETED

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Georgetown University

NCT06069778 TERMINATED

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

BioNTech SE

NCT05169437 TERMINATED

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

Tempus AI

NCT03192462 COMPLETED

TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

Baylor College of Medicine

NCT04390763 TERMINATED

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Novartis Pharmaceuticals

NCT05494697 SUSPENDED

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

AIM ImmunoTech Inc.

NCT03404960 COMPLETED

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

University of Pennsylvania

NCT03184870 COMPLETED

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

NCT03417921 SUSPENDED

A Study of ABTL0812 in Pancreatic Cancer

Ability Pharmaceuticals SL

NCT04257448 COMPLETED

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

GWT-TUD GmbH

NCT06690281 WITHDRAWN

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

National Cancer Institute (NCI)

NCT00964171 COMPLETED

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Institut Bergonié

NCT02754726 COMPLETED

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

HonorHealth Research Institute

NCT04191421 COMPLETED

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Emory University

NCT05259696 COMPLETED

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Palleon Pharmaceuticals, Inc.

NCT04409002 COMPLETED

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Massachusetts General Hospital

NCT04493060 COMPLETED

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Mayo Clinic

NCT03697564 COMPLETED

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Hitendra Patel

NCT03033225 COMPLETED

Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study

Mayo Clinic

NCT04116073 COMPLETED

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03496662 COMPLETED

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Washington University School of Medicine

NCT06266143 COMPLETED

A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer

Wuhan YZY Biopharma Co., Ltd.

NCT01781728 COMPLETED

Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01342354 COMPLETED

Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer

University of Chicago

NCT05239182 TERMINATED

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Anwaar Saeed

NCT04992507 TERMINATED

Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study

Ohio State University Comprehensive Cancer Center

NCT05563272 TERMINATED

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Telix Pharmaceuticals (Innovations) Pty Ltd

NCT02611024 COMPLETED

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

NCT02723331 COMPLETED

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Academic Thoracic Oncology Medical Investigators Consortium

NCT03693677 COMPLETED

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

Federation Francophone de Cancerologie Digestive

NCT06592664 WITHDRAWN

Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

Lisata Therapeutics, Inc.

NCT05546476 COMPLETED

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

Pfizer

NCT04068896 COMPLETED

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NGM Biopharmaceuticals, Inc

NCT03250273 COMPLETED

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06241352 COMPLETED

Statin Addition to Chemotherapy for Advanced Pancreatic Cancer

Changhai Hospital

NCT01144455 COMPLETED

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

ImmunoGenesis

NCT01834235 TERMINATED

QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

Precision Biologics, Inc

NCT05251233 TERMINATED

Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy

Washington University School of Medicine

NCT01555489 TERMINATED

Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca

Thomas Jefferson University

NCT02632448 COMPLETED

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Esperas Pharma Inc.

NCT00640978 TERMINATED

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

NCT03374852 WITHDRAWN

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT03610490 TERMINATED

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

M.D. Anderson Cancer Center

NCT05673811 COMPLETED

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Theriva Biologics SL

NCT04383210 TERMINATED

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

NCT03829501 TERMINATED

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Kymab Limited

NCT02650804 COMPLETED

BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

BPGbio

NCT06111872 COMPLETED

Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

National University of Malaysia

NCT05360264 TERMINATED

tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr

Luca Cardone

NCT02879318 COMPLETED

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Canadian Cancer Trials Group

NCT04976660 WITHDRAWN

TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors

Tarus Therapeutics, Inc.

NCT01601808 COMPLETED

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

University of Liverpool

NCT04247165 COMPLETED

Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

Herlev Hospital

NCT03058289 COMPLETED

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Intensity Therapeutics, Inc.

NCT03563144 WITHDRAWN

QUILT-3.088: NANT Pancreatic Cancer Vaccine

ImmunityBio, Inc.

NCT02907099 COMPLETED

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

NCT03822936 TERMINATED

Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma

CNAO National Center of Oncological Hadrontherapy

NCT04386057 COMPLETED

LY3214996 +/- HCQ in Pancreatic Cancer

Kimberly Perez, MD

NCT04666688 COMPLETED

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PureTech

NCT03161379 COMPLETED

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04662112 COMPLETED

Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma

Asan Medical Center

NCT03699319 COMPLETED

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

David Bajor, MD

NCT05031494 COMPLETED

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

Eucure (Beijing) Biopharma Co., Ltd

NCT02581215 COMPLETED

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Walid Shaib, MD

NCT05861336 WITHDRAWN

GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

NCT03974854 TERMINATED

Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma

Centre Hospitalier Universitaire de Besancon

NCT04731467 COMPLETED

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Famewave Ltd.

NCT03997968 COMPLETED

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

NCT05546411 TERMINATED

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Kimberly Perez, MD

NCT03329248 TERMINATED

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

ImmunityBio, Inc.

NCT01905150 COMPLETED

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Bruckner Oncology

NCT03225989 COMPLETED

Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer

Lokon Pharma AB

NCT01064622 COMPLETED

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

NCT03592264 TERMINATED

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

OBI Pharma, Inc

NCT03207867 TERMINATED

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Novartis Pharmaceuticals

NCT03006302 COMPLETED

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04536077 TERMINATED

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Washington University School of Medicine

NCT04683939 TERMINATED

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

BioNTech SE

NCT02677038 COMPLETED

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

M.D. Anderson Cancer Center

NCT04098432 COMPLETED

STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma

University Hospital Hradec Kralove

NCT03269526 COMPLETED

BATs Treatment for Pancreatic Cancer, Phase Ib/II

University of Virginia

NCT04156087 COMPLETED

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

Baki Topal

NCT02745197 WITHDRAWN

A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer

University of Alberta

NCT05052567 COMPLETED

CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

Qilu Pharmaceutical Co., Ltd.

NCT02826486 COMPLETED

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients

BioLineRx, Ltd.

NCT02431676 COMPLETED

Survivorship Promotion In Reducing IGF-1 Trial

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03586869 TERMINATED

QUILT-3.080: NANT Pancreatic Cancer Vaccine

ImmunityBio, Inc.

NCT03486327 TERMINATED

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

Bracco Diagnostics, Inc

NCT03267316 COMPLETED

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

Cantargia AB

NCT00819169 TERMINATED

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

NantCell, Inc.

NCT04228601 COMPLETED

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT06518538 WITHDRAWN

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

Cornerstone Pharmaceuticals

NCT01595321 COMPLETED

Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03190265 COMPLETED

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03127098 TERMINATED

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

NCT02697058 COMPLETED

Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer

Institut de Recherches Internationales Servier

NCT03336216 COMPLETED

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Bristol-Myers Squibb

NCT06398587 WITHDRAWN

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

OHSU Knight Cancer Institute

NCT02352337 COMPLETED

First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem

Federation Francophone de Cancerologie Digestive

NCT02827201 COMPLETED

FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine

Federation Francophone de Cancerologie Digestive

NCT03077685 COMPLETED

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

NanOlogy, LLC

NCT03136406 TERMINATED

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

ImmunityBio, Inc.

NCT01580397 COMPLETED

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

ImmunityBio, Inc.

NCT05116917 TERMINATED

Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.

Herlev Hospital

NCT03450018 TERMINATED

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

British Columbia Cancer Agency

NCT03387098 TERMINATED

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

ImmunityBio, Inc.

NCT04698915 TERMINATED

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Galera Therapeutics, Inc.

NCT04090463 SUSPENDED

IORT on Borderline Resectable Pancreatic Cancer

Universita di Verona

NCT04390243 TERMINATED

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Academic and Community Cancer Research United

NCT03146962 COMPLETED

High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies

Weill Medical College of Cornell University

NCT04808362 TERMINATED

Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

Peptomyc S.L.

NCT03848182 TERMINATED

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

Albert Einstein College of Medicine

NCT03127124 WITHDRAWN

QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer

NantPharma, LLC

NCT04431258 COMPLETED

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Ability Pharmaceuticals SL

NCT04617067 COMPLETED

Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

Cancer Trials Ireland

NCT02128100 COMPLETED

Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

University of Louisville

NCT06278493 COMPLETED

A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT04177810 COMPLETED

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01959139 COMPLETED

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

SWOG Cancer Research Network

NCT01525082 COMPLETED

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Shaheen Shagufta

NCT03376659 TERMINATED

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Georgetown University

NCT04624217 COMPLETED

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT03340974 COMPLETED

Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer

Galera Therapeutics, Inc.

NCT03189914 COMPLETED

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Processa Pharmaceuticals

NCT01897454 TERMINATED

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Albert Einstein College of Medicine

NCT04637698 TERMINATED

OH2 Oncolytic Viral Therapy in Pancreatic Cancer

Binhui Biopharmaceutical Co., Ltd.

NCT02527434 COMPLETED

Study of Tremelimumab in Patients With Advanced Solid Tumors

AstraZeneca

NCT04565327 TERMINATED

Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma

Zhen Wang, MD

NCT02178436 COMPLETED

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Mohammed Najeeb Al Hallak

NCT00625586 TERMINATED

Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

MacroGenics

NCT04983407 TERMINATED

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Aravive, Inc.

NCT02383433 TERMINATED

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Case Comprehensive Cancer Center

NCT03714555 TERMINATED

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

HonorHealth Research Institute

NCT03117920 COMPLETED

A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer

Minneamrita Therapeutics LLC

NCT01959672 COMPLETED

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

University of Nebraska

NCT02504333 COMPLETED

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

NCT03611556 COMPLETED

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

MedImmune LLC

NCT05906615 COMPLETED

Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT03140670 TERMINATED

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Abramson Cancer Center at Penn Medicine

NCT02866383 COMPLETED

Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients

Herlev Hospital

NCT03953235 COMPLETED

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Gritstone bio, Inc.

NCT02427841 COMPLETED

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

OHSU Knight Cancer Institute

NCT01470417 COMPLETED

Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

University of Florida

NCT04953962 COMPLETED

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

CanBas Co. Ltd.

NCT01726582 COMPLETED

Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")

Medical College of Wisconsin

NCT03602079 COMPLETED

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

NCT05926206 WITHDRAWN

Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas

University of Michigan Rogel Cancer Center

NCT03576131 TERMINATED

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Genmab

NCT02324543 COMPLETED

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00965718 COMPLETED

Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer

GC Cell Corporation

NCT04212026 TERMINATED

Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.

University Hospital, Basel, Switzerland

NCT02775695 COMPLETED

Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer

Medical College of Wisconsin

NCT02047513 COMPLETED

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

AIO-Studien-gGmbH

NCT02042378 COMPLETED

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

pharmaand GmbH

NCT03745430 COMPLETED

RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Hellenic Cooperative Oncology Group

NCT02620865 COMPLETED

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Barbara Ann Karmanos Cancer Institute

NCT01845337 COMPLETED

Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine

University of Edinburgh

NCT05251038 WITHDRAWN

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Devalingam Mahalingam

NCT02578732 COMPLETED

FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

Brown University

NCT02194829 COMPLETED

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT02511223 COMPLETED

Efficacy and Safety of PARPi to Treat Pancreatic Cancer

Sheba Medical Center

NCT03410030 COMPLETED

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

HonorHealth Research Institute

NCT02806687 COMPLETED

Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer

University Hospital, Toulouse

NCT03717298 COMPLETED

Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Catalysis SL

NCT03801915 COMPLETED

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

National Cancer Institute (NCI)

NCT02707159 COMPLETED

Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients

Helse Stavanger HF

NCT02210559 COMPLETED

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Kyntra Bio

NCT02028806 COMPLETED

mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer

Yuhong Li

NCT02426281 COMPLETED

Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Samsung Medical Center

NCT04224402 COMPLETED

Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Yuhong Li

NCT01647828 COMPLETED

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

OncoMed Pharmaceuticals, Inc.

NCT03977272 COMPLETED

Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer

Zhejiang University

NCT02713529 COMPLETED

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

AmMax Bio, Inc.

NCT03331562 COMPLETED

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Translational Genomics Research Institute

NCT03214250 COMPLETED

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Parker Institute for Cancer Immunotherapy

NCT01939665 COMPLETED

PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma

Amsterdam UMC, location VUmc

NCT02564146 COMPLETED

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine

AIO-Studien-gGmbH

NCT03318497 COMPLETED

Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

University of Texas Southwestern Medical Center

NCT02428270 COMPLETED

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

University Health Network, Toronto

NCT03099265 TERMINATED

Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma

Yale University

NCT02562716 COMPLETED

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

SWOG Cancer Research Network

NCT02551991 COMPLETED

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Ipsen

NCT03723915 TERMINATED

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Northwestern University

NCT01845805 COMPLETED

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03158779 COMPLETED

Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer

Istituto Clinico Humanitas

NCT01547260 COMPLETED

Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer

Maria Liljefors

NCT04769414 COMPLETED

Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)

Menoufia University

NCT02080221 COMPLETED

BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

Brown University

NCT03559348 COMPLETED

Locally Advanced or Metastatic Pancreatic Adenocarcinoma

National Health Research Institutes, Taiwan

NCT03086369 COMPLETED

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

NCT05212025 WITHDRAWN

Adavosertib and Gemcitabine in Advanced Pancreatic

James Cleary, MD, PhD

NCT01461915 TERMINATED

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

Jazz Pharmaceuticals

NCT02022033 COMPLETED

BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

Brown University

NCT04327986 TERMINATED

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

National Cancer Institute (NCI)

NCT02704156 COMPLETED

SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer

Changhai Hospital

NCT02850874 WITHDRAWN

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Wake Forest University Health Sciences

NCT02080260 COMPLETED

A Study of Regorafenib in Advanced Pancreatic Cancer Patients

Wake Forest University Health Sciences

NCT02178709 COMPLETED

A Phase II Study of Neoadjuvant FOLFIRINOX

Indiana University

NCT04258150 TERMINATED

Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer

Herlev Hospital

NCT01360593 COMPLETED

Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma

David A. Clump, MD, PhD

NCT02131493 COMPLETED

S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer

Zhejiang University

NCT00617708 COMPLETED

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

NCT03637491 TERMINATED

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Pfizer

NCT04790695 COMPLETED

Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab

Ottawa Hospital Research Institute

NCT03331640 TERMINATED

A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy

AIO-Studien-gGmbH

NCT04105062 WITHDRAWN

LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery

Washington University School of Medicine

NCT04070313 TERMINATED

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

TTY Biopharm

NCT01303172 COMPLETED

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Immodulon Therapeutics Ltd

NCT01660711 COMPLETED

A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma

Endeavor Health

NCT03023722 COMPLETED

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

Yale University

NCT03599362 TERMINATED

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

NYU Langone Health

NCT03261947 COMPLETED

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Millennium Pharmaceuticals, Inc.

NCT00603863 COMPLETED

Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer

Gilead Sciences

NCT01631552 COMPLETED

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

NCT01666730 COMPLETED

Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer

Case Comprehensive Cancer Center

NCT03451773 TERMINATED

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

National Cancer Institute (NCI)

NCT01459614 COMPLETED

Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01053013 COMPLETED

Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer

The Rogosin Institute

NCT04464967 WITHDRAWN

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

NCT02562898 COMPLETED

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Margaret Tempero

NCT01210911 COMPLETED

Metformin Combined With Chemotherapy for Pancreatic Cancer

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT01077986 COMPLETED

Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT02311361 COMPLETED

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

NCT02985801 TERMINATED

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Massimo Raimondo, M.D.

NCT01206296 TERMINATED

Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma

Medstar Health Research Institute

NCT01839799 COMPLETED

A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma

Abramson Cancer Center at Penn Medicine

NCT03040986 COMPLETED

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

National Cancer Institute (NCI)

NCT02921737 TERMINATED

TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)

University of Florida

NCT03415802 COMPLETED

Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer

Aiping Zhou

NCT03585062 TERMINATED

Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer

Zhejiang Provincial People's Hospital

NCT01652976 COMPLETED

Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma

University of Florida

NCT01964287 COMPLETED

First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.

Institut du Cancer de Montpellier - Val d'Aurelle

NCT03979066 TERMINATED

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

Gulam Manji

NCT01562899 TERMINATED

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Pfizer

NCT03042780 TERMINATED

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

NCT04262388 WITHDRAWN

A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation

University Health Network, Toronto

NCT01397019 COMPLETED

Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours

Per Pfeiffer

NCT03180437 COMPLETED

Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer

Fuda Cancer Hospital, Guangzhou

NCT02459652 COMPLETED

Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer

Japan Adjuvant Study Group of Pancreatic Cancer

NCT03509298 WITHDRAWN

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer

Fuda Cancer Hospital, Guangzhou

NCT02289898 COMPLETED

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

OncoMed Pharmaceuticals, Inc.

NCT03038477 WITHDRAWN

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

University of Colorado, Denver

NCT00769483 COMPLETED

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

NCT03213626 TERMINATED

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Patrick Joseph Loehrer Sr.

NCT01560949 COMPLETED

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

M.D. Anderson Cancer Center

NCT03469258 TERMINATED

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

Dana-Farber Cancer Institute

NCT01222689 COMPLETED

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

NCT00882765 WITHDRAWN

Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Jonsson Comprehensive Cancer Center

NCT01839487 COMPLETED

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Halozyme Therapeutics

NCT03168139 COMPLETED

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer

TME Pharma AG

NCT02405585 TERMINATED

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

NewLink Genetics Corporation

NCT00614601 TERMINATED

Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer

NewLink Genetics Corporation

NCT01896869 COMPLETED

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02261714 COMPLETED

Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

Targovax ASA

NCT03344172 TERMINATED

Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer

Nathan Bahary, MD

NCT02628860 COMPLETED

Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy

National Cancer Center, Korea

NCT02713984 WITHDRAWN

A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer

Zhi Yang

NCT04058964 WITHDRAWN

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

NCT01693523 COMPLETED

Minocycline Study in Pancreatic Cancer Patients

M.D. Anderson Cancer Center

NCT00727441 COMPLETED

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01392352 TERMINATED

HYPAZ: Hypertension Induced by Pazopanib

Cambridge University Hospitals NHS Foundation Trust

NCT04134468 WITHDRAWN

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

NCT02743975 TERMINATED

Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma

University Medical Center Groningen

NCT01431794 TERMINATED

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02358161 COMPLETED

Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT02541370 COMPLETED

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Chinese PLA General Hospital

NCT03300843 TERMINATED

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

National Cancer Institute (NCI)

NCT01240304 TERMINATED

A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas

University of Arkansas

NCT00728000 WITHDRAWN

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

University of Cincinnati

NCT02749136 COMPLETED

Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer

Asan Medical Center

NCT02981342 COMPLETED

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

Eli Lilly and Company

NCT03891472 COMPLETED

Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer

Medical University of Silesia

NCT01661088 COMPLETED

A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients

University of Michigan Rogel Cancer Center

NCT02106884 COMPLETED

Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel

Universitaire Ziekenhuizen KU Leuven

NCT00733746 COMPLETED

Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Alliance for Clinical Trials in Oncology

NCT04130399 WITHDRAWN

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Indiana University

NCT01583686 TERMINATED

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Cancer Institute (NCI)

NCT02043730 COMPLETED

Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.

Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

NCT01806675 COMPLETED

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Sanjiv Sam Gambhir

NCT02362048 COMPLETED

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

Acerta Pharma BV

NCT01524575 WITHDRAWN

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

University of Hawaii

NCT01505530 COMPLETED

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Eli Lilly and Company

NCT02449967 WITHDRAWN

HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer

Fuda Cancer Hospital, Guangzhou

NCT01028495 COMPLETED

A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Rexahn Pharmaceuticals, Inc.

NCT03008304 COMPLETED

High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer

Fuda Cancer Hospital, Guangzhou

NCT02718859 COMPLETED

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Fuda Cancer Hospital, Guangzhou

NCT02570711 TERMINATED

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Acerta Pharma BV

NCT02352831 TERMINATED

Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Washington University School of Medicine

NCT02583477 COMPLETED

Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

AstraZeneca

NCT01858883 COMPLETED

Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Incyte Corporation

NCT02124369 TERMINATED

Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)

CCTU- Cancer Theme

NCT03529175 COMPLETED

Scheduling Nab-paclitaxel With Gemcitabine

CCTU- Cancer Theme

NCT01313416 TERMINATED

Gemcitabine and CT-011 for Resected Pancreatic Cancer

Augusta University

NCT02736578 TERMINATED

Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

Eben Rosenthal

NCT01132755 COMPLETED

Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage

Memorial Sloan Kettering Cancer Center

NCT03697239 WITHDRAWN

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Hitendra Patel

NCT03797443 WITHDRAWN

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Piedmont Cancer Institute

NCT03432676 WITHDRAWN

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

NCT03908333 WITHDRAWN

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Medical College of Wisconsin

NCT01893801 COMPLETED

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Pancreatic Cancer Research Team

NCT03392571 WITHDRAWN

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Pancreatic Cancer Research Team

NCT01128296 COMPLETED

Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas

Amer Zureikat

NCT01088815 COMPLETED

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00923299 COMPLETED

Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine

Institut du Cancer de Montpellier - Val d'Aurelle

NCT02910882 TERMINATED

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer

Scripps Health

NCT02950025 TERMINATED

Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

Washington University School of Medicine

NCT00735917 COMPLETED

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

NCT01978184 COMPLETED

Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine

Nathan Bahary, MD

NCT01760252 TERMINATED

Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol

Beth Israel Medical Center

NCT01233375 COMPLETED

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

Clovis Oncology, Inc.

NCT02440958 COMPLETED

Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial

Yonsei University

NCT02023021 COMPLETED

Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Xian-Jun Yu

NCT02005419 COMPLETED

Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Xian-Jun Yu

NCT02732938 TERMINATED

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients

Pfizer

NCT01632306 TERMINATED

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

NCT02403271 COMPLETED

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Pharmacyclics LLC.

NCT01453153 COMPLETED

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Halozyme Therapeutics

NCT03627390 COMPLETED

BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer

Meabco A/S

NCT02669914 TERMINATED

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Washington University School of Medicine

NCT01032057 COMPLETED

Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Lisette Nixon

NCT02399137 COMPLETED

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals

NCT02967770 WITHDRAWN

Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer

Georgetown University

NCT01621243 TERMINATED

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Momenta Pharmaceuticals, Inc.

NCT02558894 COMPLETED

Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

AstraZeneca

NCT02195180 COMPLETED

Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

ERYtech Pharma

NCT02241551 TERMINATED

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Nathan Bahary, MD

NCT01921751 TERMINATED

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Radiation Therapy Oncology Group

NCT02345460 TERMINATED

Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study

Case Comprehensive Cancer Center

NCT02767752 TERMINATED

Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer

Herlev Hospital

NCT02331251 TERMINATED

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Western Regional Medical Center

NCT02423954 TERMINATED

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Western Regional Medical Center

NCT02004262 COMPLETED

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

Aduro Biotech, Inc.

NCT01389440 COMPLETED

Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer

Grupo Espanol Multidisciplinario del Cancer Digestivo

NCT01373164 COMPLETED

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Eli Lilly and Company

NCT00889187 TERMINATED

Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer

Dana-Farber Cancer Institute

NCT01417000 COMPLETED

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

Aduro Biotech, Inc.

NCT01888978 COMPLETED

Molecularly Tailored Therapy for Pancreas Cancer

Georgetown University

NCT02638909 TERMINATED

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Criterium, Inc.

NCT01280058 COMPLETED

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

NCT01423604 COMPLETED

Study of Ruxolitinib in Pancreatic Cancer Patients

Incyte Corporation

NCT01851174 TERMINATED

Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

Western Regional Medical Center

NCT01781520 COMPLETED

Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer

Capital Medical University

NCT00810719 COMPLETED

Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

University of California, Davis

NCT01234935 COMPLETED

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Translational Oncology Research International

NCT01056601 TERMINATED

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Masonic Cancer Center, University of Minnesota

NCT01146054 COMPLETED

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Stanford University

NCT00903396 TERMINATED

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Alliance for Clinical Trials in Oncology

NCT01430052 COMPLETED

Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer

Osaka Medical Center for Cancer and Cardiovascular Diseases

NCT01688336 TERMINATED

FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer

UNC Lineberger Comprehensive Cancer Center

NCT01553019 COMPLETED

Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer

University of Florida

NCT01150630 COMPLETED

Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer

IRCCS San Raffaele

NCT01730222 COMPLETED

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

IRCCS San Raffaele

NCT01523457 COMPLETED

Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer

Yale University

NCT01531712 TERMINATED

Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

Institut Català d'Oncologia

NCT01195415 COMPLETED

Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer

National Cancer Institute (NCI)

NCT01040000 COMPLETED

QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Precision Biologics, Inc

NCT01303029 COMPLETED

Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

NCT02035072 COMPLETED

Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

NCT00609336 COMPLETED

Perioperative Therapy for Resectable Pancreatic Cancer

University of Washington

NCT01016483 COMPLETED

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

EMD Serono

NCT02117258 COMPLETED

Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma

Zeria Pharmaceutical

NCT01273805 COMPLETED

Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer

Dana-Farber Cancer Institute

NCT01515046 TERMINATED

Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

Joseph J. Cullen

NCT00841035 TERMINATED

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

University of Alabama at Birmingham

NCT02243007 TERMINATED

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Massachusetts General Hospital

NCT01844817 COMPLETED

Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer

SCRI Development Innovations, LLC

NCT01608711 COMPLETED

A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002

Agensys, Inc.

NCT02202785 TERMINATED

A Study of MLN0264 in Patients With Pancreatic Cancer

Millennium Pharmaceuticals, Inc.

NCT00691054 COMPLETED

Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy

University of Miami

NCT00948688 TERMINATED

Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas

Massachusetts General Hospital

NCT01558869 COMPLETED

Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

The University of Hong Kong

NCT01272791 COMPLETED

Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Peregrine Pharmaceuticals

NCT00601627 COMPLETED

Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery

Alliance for Clinical Trials in Oncology

NCT00550836 COMPLETED

Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

Alliance for Clinical Trials in Oncology

NCT00907166 TERMINATED

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

Cornerstone Pharmaceuticals

NCT01175733 COMPLETED

Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer

Amsterdam UMC, location VUmc

NCT01130142 COMPLETED

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

Infinity Pharmaceuticals, Inc.

NCT01895790 WITHDRAWN

Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer

Johns Hopkins University

NCT01108458 TERMINATED

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

George Albert Fisher

NCT01581307 COMPLETED

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

H. Lee Moffitt Cancer Center and Research Institute

NCT00944463 COMPLETED

Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients

Samsung Medical Center

NCT02242409 TERMINATED

Study of Gemcitabine and Abraxane for Pancreas Cancer

Georgetown University

NCT02109341 COMPLETED

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

Gruppo Oncologico Italiano di Ricerca Clinica

NCT03016637 COMPLETED

Pancreatic Core Biopsy Needle Study in Patients Suspected of Pancreatic Malignancy

Odense University Hospital

NCT02984501 COMPLETED

Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer

Campus Bio-Medico University

NCT01369420 COMPLETED

NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer

Angiodynamics, Inc.

NCT01661114 COMPLETED

A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

University of Michigan Rogel Cancer Center

NCT01050426 TERMINATED

A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)

Royal Marsden NHS Foundation Trust

NCT00726037 TERMINATED

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

Loyola University

NCT01188109 TERMINATED

Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

Emory University

NCT01488552 COMPLETED

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer Research Team

NCT01304160 COMPLETED

Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

Centre hospitalier de l'Université de Montréal (CHUM)

NCT02382263 COMPLETED

Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer

PH Research, S.L.

NCT01473303 WITHDRAWN

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer

Alliance for Clinical Trials in Oncology

NCT00674973 COMPLETED

A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Hoffmann-La Roche

NCT00871169 COMPLETED

Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer

New Mexico Cancer Research Alliance

NCT01416662 COMPLETED

Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Federation Francophone de Cancerologie Digestive

NCT00766636 TERMINATED

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

M.D. Anderson Cancer Center

NCT01415713 COMPLETED

The Study of Metastatic Pancreatic Adenocarcinoma

National Health Research Institutes, Taiwan

NCT01395017 COMPLETED

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Otsuka Pharmaceutical Development & Commercialization, Inc.

NCT01658943 COMPLETED

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

National Cancer Institute (NCI)

NCT01693276 TERMINATED

Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

Olugbenga Olowokure

NCT01042028 TERMINATED

A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer

Per Pfeiffer

NCT00633789 COMPLETED

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Bristol-Myers Squibb

NCT00902291 COMPLETED

A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

Astellas Pharma Inc

NCT01754623 TERMINATED

GTX-RT in Borderline Resectable Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT00733850 COMPLETED

Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

KangLaiTe USA

NCT01298011 COMPLETED

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

Pancreatic Cancer Research Team

NCT01080248 TERMINATED

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Washington University School of Medicine

NCT00743379 COMPLETED

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Threshold Pharmaceuticals

NCT01167738 TERMINATED

Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer

IRCCS San Raffaele

NCT01587534 COMPLETED

Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)

National Cancer Center, Korea

NCT00998322 COMPLETED

A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

Oncolytics Biotech

NCT01130701 WITHDRAWN

A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .

University of Massachusetts, Worcester

NCT01472198 COMPLETED

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Gilead Sciences

NCT00652366 COMPLETED

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Hoffmann-La Roche

NCT01628458 COMPLETED

Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer

UMC Utrecht

NCT00962312 COMPLETED

Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer

Cancer Trials Ireland

NCT01232829 COMPLETED

Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

National Cancer Institute (NCI)

NCT01593995 COMPLETED

EGF Ointment for Erlotinib Skin Lesion

Dong-A University Hospital

NCT01339754 COMPLETED

Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy

IRCCS San Raffaele

NCT00577889 COMPLETED

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer

National Cancer Institute (NCI)

NCT01227018 TERMINATED

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Vanderbilt-Ingram Cancer Center

NCT00837876 COMPLETED

Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Vanderbilt-Ingram Cancer Center

NCT01971034 COMPLETED

Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.

Instituto do Cancer do Estado de São Paulo

NCT01020006 COMPLETED

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Pharmacyclics LLC.

NCT01124786 COMPLETED

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Clovis Oncology, Inc.

NCT01505413 COMPLETED

Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer

Soonchunhyang University Hospital

NCT00636883 TERMINATED

Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer

National Guard Health Affairs

NCT00910741 COMPLETED

NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia

NanoCarrier Co., Ltd.

NCT01096732 TERMINATED

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)

Lisa Bax

NCT01830322 WITHDRAWN

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Cornerstone Pharmaceuticals

NCT00837031 COMPLETED

Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas

SCRI Development Innovations, LLC

NCT00959946 TERMINATED

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Pfizer

NCT00922896 COMPLETED

Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer

Gyeongsang National University Hospital

NCT00709826 COMPLETED

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

Tragara Pharmaceuticals, Inc.

NCT00862524 COMPLETED

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Array BioPharma

NCT01186731 COMPLETED

Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer

INSYS Therapeutics Inc

NCT01196247 COMPLETED

A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

Translational Drug Development

NCT01320241 COMPLETED

Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture

Southeast University, China

NCT01543412 COMPLETED

Second Line Chemotherapy for Advanced Pancreatic Cancer

Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

NCT00831493 TERMINATED

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

M.D. Anderson Cancer Center

NCT00967603 COMPLETED

Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer

IRCCS San Raffaele

NCT00898287 COMPLETED

Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

Piramal Enterprises Limited

NCT00673504 COMPLETED

First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

Central European Society for Anticancer Drug Research

NCT00683085 TERMINATED

Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Tokyo University

NCT00810953 COMPLETED

A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy

Oncozyme Pharma Inc.

NCT00761241 COMPLETED

Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT

Benaroya Research Institute

NCT00637364 SUSPENDED

High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain

CMED HIFU Development Corporation

NCT05708950 COMPLETED

A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Kineta Inc.

NCT01821729 COMPLETED

Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer

Massachusetts General Hospital

NCT05005403 RECRUITING

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AbbVie

NCT07583771 NOT YET RECRUITING

A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

Chipscreen Biosciences, Ltd.

NCT06549751 NOT YET RECRUITING

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Marker Therapeutics, Inc.

NCT06673329 RECRUITING

Brodalumab in the Treatment of Immune-Related Adverse Events

Brian Henick, MD

NCT03816358 ACTIVE NOT RECRUITING

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

National Cancer Institute (NCI)

NCT02595931 ACTIVE NOT RECRUITING

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT05877599 RECRUITING

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

AstraZeneca

NCT06465069 RECRUITING

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Eli Lilly and Company

NCT04106856 ACTIVE NOT RECRUITING

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer (SHAPER)

University of Utah

NCT07458347 RECRUITING

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Kestrel Therapeutics, Inc.

NCT06141031 RECRUITING

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

NCT04389632 RECRUITING

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT04627246 ACTIVE NOT RECRUITING

Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer

Centre Hospitalier Universitaire Vaudois

NCT04104672 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Arcus Biosciences, Inc.

NCT07300150 RECRUITING

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

PAQ Therapeutics, Inc.

NCT06835569 RECRUITING

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Alterome Therapeutics, Inc.

NCT05365581 RECRUITING

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Global Development, Inc.

NCT07566897 NOT YET RECRUITING

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

Philogen S.p.A.

NCT05799274 RECRUITING

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Radiopharm Theranostics, Ltd

NCT07549958 RECRUITING

PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

University of California, Irvine

NCT06218914 RECRUITING

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

AstraZeneca

NCT07481383 RECRUITING

A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

Continuity Biosciences, LLC

NCT07117032 RECRUITING

Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain

Case Comprehensive Cancer Center

NCT06892054 RECRUITING

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

NCT07021066 RECRUITING

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

SystImmune Inc.

NCT06648434 RECRUITING

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

NCT07488884 NOT YET RECRUITING

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

ImmunityBio, Inc.

NCT02495896 ACTIVE NOT RECRUITING

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

University of Southern California

NCT07553793 NOT YET RECRUITING

Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients

Peking Union Medical College Hospital

NCT07261631 RECRUITING

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Novartis Pharmaceuticals

NCT06147037 RECRUITING

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

AstraZeneca

NCT06562192 RECRUITING

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Novartis Pharmaceuticals

NCT04222413 RECRUITING

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

National Cancer Institute (NCI)

NCT02600949 ENROLLING BY INVITATION

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

M.D. Anderson Cancer Center

NCT00669734 ACTIVE NOT RECRUITING

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

NCT06607185 ACTIVE NOT RECRUITING

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

NCT05208762 RECRUITING

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT06131840 RECRUITING

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT06586515 RECRUITING

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Eli Lilly and Company

NCT07127874 RECRUITING

A Study of PHN-012 in Patients With Advanced Solid Tumors

Pheon Therapeutics

NCT05394259 RECRUITING

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

M.D. Anderson Cancer Center

NCT07094204 RECRUITING

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Astellas Pharma Inc

NCT06026410 RECRUITING

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Kura Oncology, Inc.

NCT02381561 ACTIVE NOT RECRUITING

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

National Cancer Institute (NCI)

NCT06454383 RECRUITING

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

City of Hope Medical Center

NCT01660971 ACTIVE NOT RECRUITING

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT00878163 ACTIVE NOT RECRUITING

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT06238479 ACTIVE NOT RECRUITING

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Eli Lilly and Company

NCT05462717 ACTIVE NOT RECRUITING

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Revolution Medicines, Inc.

NCT07090499 RECRUITING

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Pfizer

NCT06639724 RECRUITING

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

University of California, San Diego

NCT06673017 RECRUITING

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

PanTher Therapeutics

NCT07277413 RECRUITING

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

IDEAYA Biosciences

NCT05846516 ACTIVE NOT RECRUITING

A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer

Boehringer Ingelheim

NCT05984602 ACTIVE NOT RECRUITING

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NYU Langone Health

NCT06917079 RECRUITING

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

NCT04484909 ACTIVE NOT RECRUITING

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

M.D. Anderson Cancer Center

NCT05143970 ACTIVE NOT RECRUITING

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

Institut Paoli-Calmettes

NCT07454642 RECRUITING

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Avacta Life Sciences Ltd

NCT04678648 RECRUITING

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

RasCal Therapeutics, Inc.

NCT07481357 RECRUITING

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

Dong-A ST Co., Ltd.

NCT06882746 RECRUITING

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

Boehringer Ingelheim

NCT07024615 RECRUITING

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Astellas Pharma Global Development, Inc.

NCT03875820 ACTIVE NOT RECRUITING

Phase I Trial of Defactinib and VS-6766.

Institute of Cancer Research, United Kingdom

NCT07189195 RECRUITING

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

University of California, Davis

NCT07227168 RECRUITING

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Sutro Biopharma, Inc.

NCT04900818 RECRUITING

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

I-Mab Biopharma US Limited

NCT06910657 RECRUITING

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

NCT07425483 RECRUITING

CAR-NK Cells (CL-NK-003) in Pancreatic Cancer

Changhai Hospital

NCT07066657 RECRUITING

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

ArriVent BioPharma, Inc.

NCT06778863 RECRUITING

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Clasp Therapeutics, Inc.

NCT05919238 RECRUITING

Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

Impact Biotech Ltd

NCT06440005 RECRUITING

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Angiex, Inc.

NCT05239143 ACTIVE NOT RECRUITING

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Poseida Therapeutics, Inc.

NCT03740256 RECRUITING

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

Baylor College of Medicine

NCT06203821 NOT YET RECRUITING

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Aram Hezel

NCT06217666 NOT YET RECRUITING

Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

Haoming (Carl) Qiu

NCT07349537 RECRUITING

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Revolution Medicines, Inc.

NCT02336087 ACTIVE NOT RECRUITING

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

NCT07030283 RECRUITING

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

University of Colorado, Denver

NCT04150042 RECRUITING

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

General Oncology, Inc.

NCT07377045 RECRUITING

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

Oncomatryx Biopharma S.L.

NCT06821048 RECRUITING

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

Weijia Fang, MD

NCT06084481 ACTIVE NOT RECRUITING

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

AbbVie

NCT07348107 NOT YET RECRUITING

ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

Daniel Breadner

NCT06458712 RECRUITING

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Duke Street Bio Ltd

NCT06059001 ACTIVE NOT RECRUITING

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

Peptomyc S.L.

NCT04673448 ACTIVE NOT RECRUITING

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

University of Washington

NCT06898385 RECRUITING

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

Sun Yat-sen University

NCT04161755 ACTIVE NOT RECRUITING

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Memorial Sloan Kettering Cancer Center

NCT06999187 RECRUITING

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Dren Bio

NCT07314385 NOT YET RECRUITING

NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer

National Taiwan University Hospital

NCT06411691 RECRUITING

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05539430 ACTIVE NOT RECRUITING

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Legend Biotech USA Inc

NCT03257761 ACTIVE NOT RECRUITING

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

NCT05245500 RECRUITING

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Bristol-Myers Squibb

NCT05013216 RECRUITING

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04117087 ACTIVE NOT RECRUITING

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05723107 RECRUITING

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

NYU Langone Health

NCT05034627 ACTIVE NOT RECRUITING

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

OHSU Knight Cancer Institute

NCT03983954 ACTIVE NOT RECRUITING

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

NCT07106827 RECRUITING

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

West China Hospital

NCT06981806 NOT YET RECRUITING

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

Arsen Osipov

NCT02207465 ACTIVE NOT RECRUITING

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

NCT06396091 ACTIVE NOT RECRUITING

A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

Astellas Pharma Global Development, Inc.

NCT03889795 ACTIVE NOT RECRUITING

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

Danae Hamouda, MD

NCT05783622 ACTIVE NOT RECRUITING

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Janux Therapeutics

NCT06182072 RECRUITING

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

ProDa BioTech, LLC

NCT04361708 RECRUITING

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

University of Chicago

NCT06896188 RECRUITING

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

Anwaar Saeed

NCT04523987 ACTIVE NOT RECRUITING

A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

National University Hospital, Singapore

NCT05163028 ACTIVE NOT RECRUITING

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

HUYABIO International, LLC.

NCT06500052 RECRUITING

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

NCT06533332 RECRUITING

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

EtiraRx Australia Pty Ltd

NCT05227326 RECRUITING

AOH1996 for the Treatment of Refractory Solid Tumors

City of Hope Medical Center

NCT05721846 ACTIVE NOT RECRUITING

Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer

Inna Chen, MD

NCT03854110 ACTIVE NOT RECRUITING

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Geistlich Pharma AG

NCT03454035 RECRUITING

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

UNC Lineberger Comprehensive Cancer Center

NCT05209074 ACTIVE NOT RECRUITING

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Case Comprehensive Cancer Center

NCT05076760 RECRUITING

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Memgen, Inc.

NCT06040541 RECRUITING

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Revolution Medicines, Inc.

NCT06508307 RECRUITING

A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors

GONGCHU Biotechnology Co., Ltd

NCT06756035 RECRUITING

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Context Therapeutics Inc.

NCT06205849 RECRUITING

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

University of California, San Diego

NCT05141513 RECRUITING

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05055323 ACTIVE NOT RECRUITING

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

Thomas Jefferson University

NCT05607953 ACTIVE NOT RECRUITING

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

TriSalus Life Sciences, Inc.

NCT05277766 RECRUITING

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

University Hospital, Ghent

NCT05057715 ACTIVE NOT RECRUITING

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

University of Pennsylvania

NCT07014878 NOT YET RECRUITING

A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors

Beijing DCTY Biotech Co.,Ltd.

NCT06596915 RECRUITING

Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

Shandong Boan Biotechnology Co., Ltd

NCT05740956 RECRUITING

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

NCT04477343 RECRUITING

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

University of Rochester

NCT06816823 RECRUITING

CAR-NK Cells (CL-NK-001) in Pancreatic Cancer

Changhai Hospital

NCT04157127 RECRUITING

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

Diakonos Oncology Corporation

NCT06337084 RECRUITING

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Monopar Therapeutics

NCT04616534 ACTIVE NOT RECRUITING

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

National Cancer Institute (NCI)

NCT06617169 RECRUITING

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Monopar Therapeutics

NCT04137536 ACTIVE NOT RECRUITING

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT05919537 ACTIVE NOT RECRUITING

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Hummingbird Bioscience

NCT06532331 ACTIVE NOT RECRUITING

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

Ono Pharmaceutical Co., Ltd.

NCT05083780 ACTIVE NOT RECRUITING

Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer

Changhoon Yoo

NCT06278454 RECRUITING

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases

Chengdu New Radiomedicine Technology Co. LTD.

NCT04514497 ACTIVE NOT RECRUITING

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

NCT06344156 RECRUITING

Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer

Sichuan University

NCT06393400 RECRUITING

CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)

John Lenehan

NCT03096054 ACTIVE NOT RECRUITING

A CR-UK Phase I Trial of LY3143921

Cancer Research UK

NCT03252808 ACTIVE NOT RECRUITING

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Takara Bio Inc.

NCT06532344 ACTIVE NOT RECRUITING

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Ono Pharmaceutical Co., Ltd.

NCT05403554 RECRUITING

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers

Light Chain Bioscience - Novimmune SA

NCT05215574 ACTIVE NOT RECRUITING

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

NCT06614751 NOT YET RECRUITING

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Danatlas Pharmaceuticals Co., Ltd

NCT04999761 RECRUITING

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

NCT06487377 RECRUITING

IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

Shanghai Pudong Hospital

NCT05911217 RECRUITING

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

CARsgen Therapeutics Co., Ltd.

NCT06403735 RECRUITING

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

NCT06346808 NOT YET RECRUITING

Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC

Sichuan University

NCT06229496 RECRUITING

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma

Chang Gung Memorial Hospital

NCT06134960 NOT YET RECRUITING

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

Peking University

NCT07594964 RECRUITING

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

Shenzhen Xinhe Biomedical

NCT07594067 NOT YET RECRUITING

TCR1188-ABC Cells in KRAS-mutated Cancers

University of Pennsylvania

NCT07589205 RECRUITING

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

NCT07587827 NOT YET RECRUITING

Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

Centre Georges Francois Leclerc

NCT07608627 NOT YET RECRUITING

64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer

City of Hope Medical Center

NCT07630961 RECRUITING

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Novartis Pharmaceuticals

NCT07619313 NOT YET RECRUITING

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Jonsson Comprehensive Cancer Center

NCT07624214 NOT YET RECRUITING

Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

NCT07645651 NOT YET RECRUITING

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

University of Washington

NCT07637786 NOT YET RECRUITING

Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer

Sichuan University

NCT07671339 RECRUITING

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT05685602 SUSPENDED

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

NCT05411094 SUSPENDED

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

NCT03851237 COMPLETED

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

Washington University School of Medicine

NCT06091930 COMPLETED

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Boehringer Ingelheim

NCT03552718 COMPLETED

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

NantBioScience, Inc.

NCT05111353 COMPLETED

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

Washington University School of Medicine

NCT05983133 TERMINATED

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT07173374 SUSPENDED

Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study

Shandong Cancer Hospital and Institute

NCT05085548 COMPLETED

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

ProDa BioTech, LLC

NCT05867121 COMPLETED

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Genentech, Inc.

NCT00885066 COMPLETED

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Centre Antoine Lacassagne

NCT04158635 SUSPENDED

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

City of Hope Medical Center

NCT03403049 COMPLETED

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Montefiore Medical Center

NCT04132505 COMPLETED

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

NCT05411133 COMPLETED

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Arbele Pty Ltd

NCT06599502 TERMINATED

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

AstraZeneca

NCT06585488 TERMINATED

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

BeOne Medicines

NCT06287463 TERMINATED

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Deciphera Pharmaceuticals, LLC

NCT03065062 SUSPENDED

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

NCT06378047 COMPLETED

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT05546853 COMPLETED

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

University Hospital, Grenoble

NCT06528093 TERMINATED

A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Boehringer Ingelheim

NCT03323944 TERMINATED

CAR T Cell Immunotherapy for Pancreatic Cancer

University of Pennsylvania

NCT05827614 TERMINATED

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Boundless Bio, Inc.

NCT05360680 COMPLETED

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Cue Biopharma

NCT06466187 TERMINATED

A Study of SGN-MesoC2 in Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT06076837 TERMINATED

The Seven Trial: Exploiting the Unfolded Protein Response

HonorHealth Research Institute

NCT06626256 WITHDRAWN

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

City of Hope Medical Center

NCT05977322 TERMINATED

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

Novartis Pharmaceuticals

NCT06199466 TERMINATED

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

NCT06129422 COMPLETED

Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

Nihon Medi-Physics Co., Ltd.

NCT02639026 COMPLETED

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Abramson Cancer Center at Penn Medicine

NCT05417386 TERMINATED

FOLFIRINOX + NIS793 in Pancreatic Cancer

Colin D. Weekes, M.D., PhD

NCT05252390 TERMINATED

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Nuvation Bio Inc.

NCT04787991 COMPLETED

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Cancer Insight, LLC

NCT06270082 TERMINATED

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Ikena Oncology

NCT04853017 COMPLETED

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Elicio Therapeutics

NCT05737615 WITHDRAWN

PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9

Memorial Sloan Kettering Cancer Center

NCT05605522 TERMINATED

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

3B Pharmaceuticals GmbH

NCT07121829 TERMINATED

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

NCT04634539 COMPLETED

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Jun Gong, MD

NCT05634525 WITHDRAWN

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

M.D. Anderson Cancer Center

NCT04580485 COMPLETED

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Incyte Corporation

NCT03592888 COMPLETED

DC Vaccine in Pancreatic Cancer

University of Pennsylvania

NCT06707896 WITHDRAWN

TCR1020-CD8 T Cells in KRAS-mutated Cancers

University of Pennsylvania

NCT05432193 TERMINATED

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

NCT05788484 COMPLETED

A Study of CDX-585 in Patients With Advanced Malignancies

Celldex Therapeutics

NCT01351103 COMPLETED

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Novartis Pharmaceuticals

NCT04292743 COMPLETED

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Georgetown University

NCT05657418 TERMINATED

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Shanghai Junshi Bioscience Co., Ltd.

NCT05440942 COMPLETED

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Peter Hosein, MD

NCT04152018 TERMINATED

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Pfizer

NCT02047500 TERMINATED

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

ImmunoGenesis

NCT04581343 COMPLETED

A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients

Pancreatic Cancer Action Network

NCT00954525 COMPLETED

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT05383352 COMPLETED

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Ipsen

NCT04796948 COMPLETED

A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT04809766 TERMINATED

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Fred Hutchinson Cancer Center

NCT03825289 TERMINATED

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

University of Utah

NCT05940844 WITHDRAWN

Study of OB-002 in Patients With Refractory Metastatic Cancer

Orion Biotechnology Polska Sp. z o.o.

NCT05737706 TERMINATED

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Mirati Therapeutics Inc.

NCT04925284 COMPLETED

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Exelixis

NCT05494866 TERMINATED

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

German Cancer Research Center

NCT03520790 TERMINATED

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Dana-Farber Cancer Institute

NCT05303090 COMPLETED

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Fudan University

NCT02345408 COMPLETED

Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

Amgen

NCT04805307 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Keymed Biosciences Co.Ltd

NCT01638533 COMPLETED

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

NCT04665921 TERMINATED

A Study of SGN-STNV in Advanced Solid Tumors

Seagen Inc.

NCT05631574 TERMINATED

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Biomea Fusion Inc.

NCT06538207 COMPLETED

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Ono Pharmaceutical Co., Ltd.

NCT04883775 COMPLETED

Study of a New Technique for Imaging Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT06469138 COMPLETED

A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

BerGenBio ASA

NCT02672917 TERMINATED

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

BioNTech Research & Development, Inc.

NCT04916236 TERMINATED

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

The Netherlands Cancer Institute

NCT04703920 COMPLETED

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

University of Michigan Rogel Cancer Center

NCT06206876 WITHDRAWN

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Roswell Park Cancer Institute

NCT02671890 TERMINATED

Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Mayo Clinic

NCT04807972 TERMINATED

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

AbbVie

NCT04164069 COMPLETED

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Anne Noonan

NCT02643498 COMPLETED

A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

NCT03549000 TERMINATED

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Novartis Pharmaceuticals

NCT03086642 COMPLETED

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Karie D. Runcie, MD

NCT01010945 COMPLETED

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

OSI Pharmaceuticals

NCT05182112 COMPLETED

Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver

Memorial Sloan Kettering Cancer Center

NCT03960060 TERMINATED

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

Shanghai PerHum Therapeutics Co., Ltd.

NCT03885284 COMPLETED

Study of Proton Therapy in Adjuvant Pancreatic Cancer

Georgetown University

NCT03087591 COMPLETED

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery

Wake Forest University Health Sciences

NCT02791334 COMPLETED

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Eli Lilly and Company

NCT04672460 COMPLETED

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Pfizer

NCT03716596 TERMINATED

SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT03517176 COMPLETED

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Lisata Therapeutics, Inc.

NCT03819387 COMPLETED

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Nitto BioPharma, Inc.

NCT03956056 TERMINATED

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Washington University School of Medicine

NCT05769959 TERMINATED

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Hoffmann-La Roche

NCT04400383 COMPLETED

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

CARsgen Therapeutics Co., Ltd.

NCT05484011 TERMINATED

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

HiberCell, Inc.

NCT03490669 COMPLETED

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

AstraZeneca

NCT01761240 COMPLETED

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Morphotek

NCT03329950 COMPLETED

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

NCT04682431 TERMINATED

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Ikena Oncology

NCT03373188 COMPLETED

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Emory University

NCT03878524 TERMINATED

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

NCT04025216 TERMINATED

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Kite, A Gilead Company

NCT04803305 COMPLETED

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Pfizer

NCT04046887 TERMINATED

Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)

Patrick Joseph Loehrer Sr.

NCT01825603 COMPLETED

ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer

University of Nebraska

NCT03454451 COMPLETED

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

NCT04299048 COMPLETED

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

Pfizer

NCT03525392 TERMINATED

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Ipsen

NCT03095781 COMPLETED

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Emory University

NCT03784677 COMPLETED

A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

M.D. Anderson Cancer Center

NCT02231723 COMPLETED

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Sumitomo Pharma America, Inc.

NCT02498665 COMPLETED

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

Sumitomo Pharma America, Inc.

NCT04247126 COMPLETED

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Syros Pharmaceuticals

NCT06017323 WITHDRAWN

Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma

Georgetown University

NCT04721301 COMPLETED

Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

University Hospital Heidelberg

NCT05650918 COMPLETED

MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)

Joachim Aerts, MD PhD

NCT03122106 TERMINATED

Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Washington University School of Medicine

NCT02897375 COMPLETED

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Emory University

NCT05395052 TERMINATED

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

NCT05043987 WITHDRAWN

Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

Conjupro Biotherapeutics, Inc.

NCT00638612 COMPLETED

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Candel Therapeutics, Inc.

NCT04050085 COMPLETED

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

University of California, Davis

NCT02959164 COMPLETED

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Mohammed Milhem

NCT01835041 COMPLETED

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Wake Forest University Health Sciences

NCT03829436 COMPLETED

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Tempest Therapeutics

NCT04990037 COMPLETED

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Cantargia AB

NCT05431582 WITHDRAWN

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

M.D. Anderson Cancer Center

NCT04193904 TERMINATED

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

4D pharma plc

NCT02333188 COMPLETED

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

University of Chicago

NCT04799431 WITHDRAWN

Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01420874 COMPLETED

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Barbara Ann Karmanos Cancer Institute

NCT02376699 TERMINATED

Safety Study of SEA-CD40 in Cancer Patients

Seagen Inc.

NCT04852367 WITHDRAWN

PanDox: Targeted Doxorubicin in Pancreatic Tumours

University of Oxford

NCT04042480 TERMINATED

A Study of SGN-CD228A in Advanced Solid Tumors

Seagen Inc.

NCT03507452 COMPLETED

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Bayer

NCT04542291 COMPLETED

Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

Washington University School of Medicine

NCT02930902 COMPLETED

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

NCT04430842 COMPLETED

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

NCT02873598 COMPLETED

A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

University of Colorado, Denver

NCT03883919 COMPLETED

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

Washington University School of Medicine

NCT02349867 COMPLETED

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

Virginia Commonwealth University

NCT00981162 COMPLETED

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Roswell Park Cancer Institute

NCT02588443 COMPLETED

Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Abramson Cancer Center at Penn Medicine

NCT02394535 COMPLETED

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

NCT04632199 WITHDRAWN

Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.

Ipsen

NCT04060342 TERMINATED

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

NCT01924260 COMPLETED

Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer

Edward Kim

NCT02227940 COMPLETED

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Roswell Park Cancer Institute

NCT01497392 COMPLETED

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Roswell Park Cancer Institute

NCT02451553 COMPLETED

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

University of Washington

NCT02514031 TERMINATED

ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

University of Texas Southwestern Medical Center

NCT01918644 COMPLETED

Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer

University of Wisconsin, Madison

NCT03412799 COMPLETED

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Panbela Therapeutics, Inc.

NCT04131192 TERMINATED

Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Sunshine Lake Pharma Co., Ltd.

NCT02702986 COMPLETED

Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)

Universita di Verona

NCT03147768 COMPLETED

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

Laser Tissue Welding, Inc.

NCT02646748 COMPLETED

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

NCT03300921 TERMINATED

A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

NCT02526017 COMPLETED

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Five Prime Therapeutics, Inc.

NCT03281382 COMPLETED

Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer

Henry Ford Health System

NCT03985072 COMPLETED

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

Andes Biotechnologies

NCT02628535 TERMINATED

Safety Study of MGD009 in B7-H3-expressing Tumors

MacroGenics

NCT00967577 COMPLETED

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Weill Medical College of Cornell University

NCT02947165 COMPLETED

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis Pharmaceuticals

NCT03319459 COMPLETED

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Fate Therapeutics

NCT03645148 COMPLETED

Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer

Zhejiang Provincial People's Hospital

NCT01523808 COMPLETED

Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer

ERYtech Pharma

NCT02777710 COMPLETED

Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

Centre Leon Berard

NCT01510561 WITHDRAWN

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Gilead Sciences

NCT02138383 COMPLETED

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT03316599 COMPLETED

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Dana-Farber Cancer Institute

NCT02546531 COMPLETED

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Washington University School of Medicine

NCT01335945 TERMINATED

Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

Boston Scientific Corporation

NCT02908451 TERMINATED

A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

AbGenomics B.V Taiwan Branch

NCT02368860 COMPLETED

OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma

National Cancer Centre, Singapore

NCT04270929 WITHDRAWN

Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma

Roger Williams Medical Center

NCT02237157 COMPLETED

A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

RenovoRx

NCT03205176 COMPLETED

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

AstraZeneca

NCT02608229 TERMINATED

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Washington University School of Medicine

NCT02048384 COMPLETED

A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02155088 COMPLETED

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT02501902 COMPLETED

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Pfizer

NCT02468557 TERMINATED

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

Gilead Sciences

NCT02154737 COMPLETED

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

Tony Reid, M.D., Ph.D.

NCT02259114 COMPLETED

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT03207724 COMPLETED

Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

Andrew Hendifar, MD

NCT02703571 TERMINATED

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Novartis Pharmaceuticals

NCT01487785 COMPLETED

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Novartis Pharmaceuticals

NCT01576666 COMPLETED

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Novartis Pharmaceuticals

NCT03291938 COMPLETED

IACS-010759 in Advanced Cancers

M.D. Anderson Cancer Center

NCT03790423 COMPLETED

18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer

Rigshospitalet, Denmark

NCT02757391 TERMINATED

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

M.D. Anderson Cancer Center

NCT02045602 COMPLETED

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Theriva Biologics SL

NCT02101580 COMPLETED

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

Polaris Group

NCT01385956 COMPLETED

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT03925428 WITHDRAWN

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

National Cancer Institute (NCI)

NCT01189929 COMPLETED

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

OncoMed Pharmaceuticals, Inc.

NCT02005315 COMPLETED

A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

OncoMed Pharmaceuticals, Inc.

NCT02050178 COMPLETED

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

OncoMed Pharmaceuticals, Inc.

NCT01485744 COMPLETED

LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer

Massachusetts General Hospital

NCT02092948 COMPLETED

Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer

Jonsson Comprehensive Cancer Center

NCT01908478 COMPLETED

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

Cedars-Sinai Medical Center

NCT03415126 COMPLETED

A Study of ASN007 in Patients With Advanced Solid Tumors

Asana BioSciences

NCT01803282 COMPLETED

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Gilead Sciences

NCT00739609 TERMINATED

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

NewLink Genetics Corporation

NCT01643499 COMPLETED

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

University of Chicago

NCT03286062 TERMINATED

VM110 in Detection of Microscopic Tumors: A Phase I Study

Fox Chase Cancer Center

NCT02681796 COMPLETED

Epidural Analgesia Use in Pancreatic Resections

Washington University School of Medicine

NCT01473940 COMPLETED

Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Northwestern University

NCT00836407 COMPLETED

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01744353 COMPLETED

BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study

Brown University

NCT02576665 TERMINATED

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Tocagen Inc.

NCT02559674 COMPLETED

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

Altor BioScience

NCT03865563 WITHDRAWN

Selective Transvenous Chemoembolization of Primary Pancreatic Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03307148 COMPLETED

Stromal TARgeting for PAncreatic Cancer (STAR_PAC)

Barts & The London NHS Trust

NCT01488513 COMPLETED

ABC294640 in Treating Patients With Advanced Solid Tumors

RedHill Biopharma Limited

NCT03811652 COMPLETED

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

MedImmune LLC

NCT02465983 TERMINATED

Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer

University of Pennsylvania

NCT02586987 COMPLETED

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

AstraZeneca

NCT02148549 COMPLETED

Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study

Wakayama Medical University

NCT02574663 COMPLETED

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

TG Therapeutics, Inc.

NCT02894944 COMPLETED

Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer

Seoul National University Hospital

NCT02734160 COMPLETED

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

NCT02707328 TERMINATED

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

The Cooper Health System

NCT01739439 TERMINATED

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

Fox Chase Cancer Center

NCT02179970 COMPLETED

To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers

CCTU- Cancer Theme

NCT02283372 COMPLETED

Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer

Washington University School of Medicine

NCT02514421 COMPLETED

Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma

The University of Texas Health Science Center, Houston

NCT02581501 WITHDRAWN

Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer

Stamford Hospital

NCT00968604 WITHDRAWN

C-VISA BikDD: Liposome in Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

NCT01188785 COMPLETED

Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas

Silenseed Ltd

NCT01537107 COMPLETED

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

Mayo Clinic

NCT02868632 WITHDRAWN

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

NYU Langone Health

NCT02782182 TERMINATED

Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

University of Chicago

NCT01984658 COMPLETED

A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients

CytoVac A/S

NCT01025882 TERMINATED

Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer

University of Texas Southwestern Medical Center

NCT02244489 TERMINATED

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Sierra Oncology LLC - a GSK company

NCT02548169 TERMINATED

Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer

Baylor Research Institute

NCT01839981 COMPLETED

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Wake Forest University Health Sciences

NCT01770132 COMPLETED

Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

John DeWitt

NCT02960594 COMPLETED

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Inovio Pharmaceuticals

NCT02592395 WITHDRAWN

Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma

The University of Texas Health Science Center, Houston

NCT01833546 COMPLETED

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Merck KGaA, Darmstadt, Germany

NCT02045589 COMPLETED

A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer

Theriva Biologics SL

NCT01663272 COMPLETED

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

University of Michigan Rogel Cancer Center

NCT02620423 COMPLETED

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Oncolytics Biotech

NCT02191761 COMPLETED

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

Biosplice Therapeutics, Inc.

NCT00783172 TERMINATED

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

Milton S. Hershey Medical Center

NCT02650635 TERMINATED

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Mayo Clinic

NCT02166255 COMPLETED

APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Wake Forest University Health Sciences

NCT01364805 COMPLETED

New Treatment Option for Pancreatic Cancer

Jeanne Drisko, MD, CNS, FACN

NCT02657330 COMPLETED

Study of SBP-101 in Pancreatic Cancer

Panbela Therapeutics, Inc.

NCT01342224 COMPLETED

Immunochemoradiotherapy in Patients With Pancreatic Cancer

Providence Health & Services

NCT01822756 TERMINATED

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

Incyte Corporation

NCT01929941 TERMINATED

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Incyte Corporation

NCT01012362 TERMINATED

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Masonic Cancer Center, University of Minnesota

NCT00703638 COMPLETED

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

NCT00667082 COMPLETED

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

NCT02272738 COMPLETED

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

Osaka Medical Center for Cancer and Cardiovascular Diseases

NCT02106871 WITHDRAWN

Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer

The University of Texas Medical Branch, Galveston

NCT01897415 COMPLETED

Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer

University of Pennsylvania

NCT01783171 COMPLETED

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT01764477 COMPLETED

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Prism Pharma Co., Ltd.

NCT01383538 COMPLETED

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

Andrew Ko

NCT01191684 COMPLETED

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

City of Hope Medical Center

NCT02651727 TERMINATED

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

Verastem, Inc.

NCT00987766 COMPLETED

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Vanderbilt-Ingram Cancer Center

NCT01386502 WITHDRAWN

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

National Cancer Institute (NCI)

NCT00654160 COMPLETED

Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer

Mayo Clinic

NCT00882973 COMPLETED

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Samyang Biopharmaceuticals Corporation

NCT01571024 COMPLETED

BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer

UNC Lineberger Comprehensive Cancer Center

NCT02567396 WITHDRAWN

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

NCT02174887 COMPLETED

Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer

Institut Paoli-Calmettes

NCT01893294 COMPLETED

Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer

Mayo Clinic

NCT00761345 COMPLETED

Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

Fox Chase Cancer Center

NCT01198821 COMPLETED

Gem-TABS in Unresectable Pancreatic Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT01946646 TERMINATED

Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer

National Taiwan University Hospital

NCT02720666 COMPLETED

K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

NCT01677962 COMPLETED

A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma

Medical University of South Carolina

NCT02210364 COMPLETED

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

PharmaMar

NCT01410968 COMPLETED

A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma

Carolyn Britten

NCT01335958 COMPLETED

Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Genentech, Inc.

NCT01521325 COMPLETED

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Morphotek

NCT01935453 COMPLETED

A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer

OrienGene Biotechnology Ltd.

NCT00837135 WITHDRAWN

GI-4000 With Adoptive Transfer in Pancreatic Cancer

University of Pennsylvania

NCT00614653 COMPLETED

Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

NCT01450046 COMPLETED

Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

H. Lee Moffitt Cancer Center and Research Institute

NCT01446952 COMPLETED

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

H. Lee Moffitt Cancer Center and Research Institute

NCT01296763 COMPLETED

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01274455 COMPLETED

Gene Therapy of Pancreatic Ductal Adenocarcinoma

University Hospital, Toulouse

NCT00574977 COMPLETED

Safety Study of Modified Vaccinia Virus to Cancer

David Bartlett

NCT01298401 COMPLETED

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Radiation Therapy Oncology Group

NCT01098344 COMPLETED

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery

Cancer Research UK

NCT01674556 COMPLETED

Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer

Haukeland University Hospital

NCT01777477 COMPLETED

Adjuvant Effect of Chloroquine on Gemcitabine

University of Zurich

NCT00925769 COMPLETED

ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer

Hoffmann-La Roche

NCT01050283 TERMINATED

A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)

Merck Sharp & Dohme LLC

NCT01954732 WITHDRAWN

Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery

Case Comprehensive Cancer Center

NCT00735306 COMPLETED

Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

Duke University

NCT00983268 COMPLETED

Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

Vanderbilt-Ingram Cancer Center

NCT01486329 COMPLETED

VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer

Vaximm GmbH

NCT02132403 TERMINATED

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

University of Illinois at Chicago

NCT02159248 WITHDRAWN

Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation

Orlando Health, Inc.

NCT02048943 WITHDRAWN

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Roswell Park Cancer Institute

NCT01131234 COMPLETED

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

NCT01834170 COMPLETED

EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer

University of Tehran

NCT01492907 COMPLETED

Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer

University of Minnesota

NCT01181245 COMPLETED

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Kyntra Bio

NCT01741597 WITHDRAWN

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung

City of Hope Medical Center

NCT01167816 TERMINATED

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

University of Oklahoma

NCT01025570 TERMINATED

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

University of California, San Francisco

NCT00878657 TERMINATED

Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer

Rutgers, The State University of New Jersey

NCT01233505 TERMINATED

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

NCT01145456 COMPLETED

Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

NCT01192763 TERMINATED

RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer

National Cancer Institute (NCI)

NCT01282333 TERMINATED

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

NCT01161186 COMPLETED

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

University of California, San Francisco

NCT01041235 COMPLETED

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Azaya Therapeutics, Inc.

NCT00556023 COMPLETED

A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

AstraZeneca

NCT01051284 COMPLETED

A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer

Georgetown University

NCT00626158 COMPLETED

Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers

University of California, San Francisco

NCT00909558 SUSPENDED

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

Envita Medical Center, Inc.

NCT07557394 NOT YET RECRUITING

A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui Tongbian Capsules Combined With Pancreatin Enteric-coated Capsules on Pancreatic Exocrine Function in Patients After Curative Resection for Pancreatic Cancer

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

NCT05634720 ACTIVE NOT RECRUITING

Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer

Duke University

NCT07302841 NOT YET RECRUITING

Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT07262957 RECRUITING

Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT04025840 ACTIVE NOT RECRUITING

Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery

Peking University First Hospital

NCT06099119 RECRUITING

Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

Hospital Clinico Universitario de Santiago

NCT06779318 NOT YET RECRUITING

Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis

The First Affiliated Hospital with Nanjing Medical University

NCT05784311 RECRUITING

Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)

Leiden University Medical Center

NCT06368063 RECRUITING

The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

Xi'an Jiaotong University

NCT06387368 NOT YET RECRUITING

Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer

Xi'an Jiaotong University

NCT05035147 RECRUITING

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT06077487 TERMINATED

Ketamine-assisted Therapy for Advanced GI Cancer

Brian Anderson, MD

NCT06199752 COMPLETED

Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal Adenocarcinoma

Theodor Bilharz Research Institute

NCT04155008 TERMINATED

Nutrition and Pharmacological Algorithm for Oncology Patients Study

Montefiore Medical Center

NCT01887041 TERMINATED

Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer

Universitätsklinikum Hamburg-Eppendorf

NCT03891979 WITHDRAWN

Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

NYU Langone Health

NCT02570529 WITHDRAWN

Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy

Yonsei University

NCT01768988 TERMINATED

Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study

Parc de Salut Mar

NCT00920023 COMPLETED

Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)

Massachusetts General Hospital

NCT00966277 COMPLETED

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

M.D. Anderson Cancer Center

NCT01041612 COMPLETED

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Taewoong Medical Co., Ltd.

NCT02027311 COMPLETED

Etomidate vs. Midazolam for Sedation During ERCP

Cheju Halla General Hospital

NCT00854477 COMPLETED

Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma

Cambridge University Hospitals NHS Foundation Trust

NCT01256034 COMPLETED

Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy

Chiba University

Full Pancreatic Cancer Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the Pancreatic Cancer landscape

How many companies are developing Pancreatic Ductal Adenocarcinoma (PDAC) treatments?: 6 companies have active or registered Pancreatic Ductal Adenocarcinoma (PDAC) programs in TheraRadar's competitive landscape (83 classified trials). The most active are Astellas Pharma Global Development, Revolution Medicines, and Amplia Therapeutics Limited.
What mechanisms of action are being developed for Pancreatic Ductal Adenocarcinoma (PDAC)?: 5 distinct mechanisms of action appear across the Pancreatic Ductal Adenocarcinoma (PDAC) pipeline, including Claudin 18.2, Pan-RAS / RAS(ON) multi, FAK, KRAS G12D, and VEGFR/Aurora B/CSF1R (multi-kinase).
What is the most crowded mechanism in Pancreatic Ductal Adenocarcinoma (PDAC)?: Claudin 18.2 is the most contested mechanism in Pancreatic Ductal Adenocarcinoma (PDAC), with 6 programs mapped to it.
Are there upcoming Pancreatic Ductal Adenocarcinoma (PDAC) clinical readouts or FDA decisions?: Near-term Pancreatic Ductal Adenocarcinoma (PDAC) catalysts include zolbetuximab (data readout, Aug '26); avutometinib (VS-6766) (data readout, Aug '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Pancreatic Ductal Adenocarcinoma (PDAC) landscape data come from?: Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Pancreatic Ductal Adenocarcinoma (PDAC) heatmap free to use?: Yes — viewing and searching the Pancreatic Ductal Adenocarcinoma (PDAC) heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.

How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

Healthy-volunteer studies are set aside as non-disease trials.
Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
🌱 First-in-indication — the only program competing on that mechanism within this disease.
🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
Sponsor names are as-filed and may lag current ownership.
Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only